

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A novel microsimulation model of tobacco use behaviors and outcomes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032579
Article Type:	Research
Date Submitted by the Author:	25-Jun-2019
Complete List of Authors:	Reddy, Krishna; Massachusetts General Hospital, Medical Practice Evaluation Center Bulteel, Alexander; Massachusetts General Hospital, Medical Practice Evaluation Center Levy, Douglas; Massachusetts General Hospital Torola, Pamela; Massachusetts General Hospital, Medical Practice Evaluation Center Hyle, Emily; Massachusetts General Hospital, Medical Practice Evaluation Center Hou, Taige; Massachusetts General Hospital, Medical Practice Evaluation Center Osher, Benjamin; Massachusetts General Hospital, Medical Practice Evaluation Center Yu, Liyang; Massachusetts General Hospital, Medical Practice Evaluation Center Shebl, Fatma; Massachusetts General Hospital, Medical Practice Evaluation Center Paltiel, A David; Yale University School of Public Health Freedberg, Kenneth; Massachusetts General Hospital, Medical Practice Evaluation Center Weinstein, Milton ; Harvard University T H Chan School of Public Health Rigotti, Nancy; Massachusetts General Hospital Walensky, Rochelle; Massachusetts General Hospital, Medical Practice Evaluation Center
Keywords:	tobacco, nicotine, model, validation, calibration, relapse

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A novel microsimulation model of tobacco use behaviors and outcomes

Krishna P. Reddy^{1,2,3,7,*}, Alexander J.B. Bulteel¹, Douglas E. Levy^{2,4,7}, Pamela Torola¹, Emily P. Hyle^{1,6,7},
Taige Hou¹, Benjamin Osher¹, Liyang Yu¹, Fatma M. Shebl^{1,7}, A. David Paltiel⁸,
Kenneth A. Freedberg^{1,5,6,7,9}, Milton C. Weinstein^{7,9}, Nancy A. Rigotti^{2,5,7}, Rochelle P. Walensky^{1,5,6,7}

¹Medical Practice Evaluation Center, ²Tobacco Research and Treatment Center, ³Division of Pulmonary and Critical Care Medicine, ⁴Mongan Institute Health Policy Research Center, ⁵Division of General Internal Medicine, and ⁶Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

⁷Harvard Medical School, Boston, MA, USA

⁸Yale School of Public Health, New Haven, CT, USA

⁹Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA

*Corresponding author:

Krishna P. Reddy, MD, MS

Medical Practice Evaluation Center

Massachusetts General Hospital

100 Cambridge Street, Suite 1600

Boston, MA 02114

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

USA

Email: kpreddy@mgh.harvard.edu

Phone: +1 617-726-1993

ABSTRACT WORD COUNT: 295

MAIN TEXT WORD COUNT: 3628

For peer review only

ABSTRACT

Background and Objective: Tobacco policymakers must consider how emerging products will change cigarette smoking behaviors and clinical outcomes. Our objective was to develop, calibrate, and validate a novel individual-level microsimulation model to project cigarette smoking behaviors and associated mortality risks. Unlike most tobacco models, our new model would explicitly include smoking relapse.

Methods: We developed the Simulating Tobacco and Nicotine Outcomes and Policy (STOP) model, in which individuals transition monthly between tobacco use states (current, former, or never) depending on rates of initiation, cessation, and relapse. Simulated individuals face tobacco use-stratified mortality risks. For US women and men, we performed internal validation of the model structure with a Cancer Intervention and Surveillance Modeling Network (CISNET) model. We then incorporated smoking relapse and calibrated cessation rates to reflect the difference between a transient quit attempt and sustained abstinence. We performed external validation with the National Health Interview Survey (NHIS) and the linked National Death Index. Comparisons were based on root-mean-square error (RMSE).

Results: In internal validation, STOP-generated projections of current/former/never smoking prevalence fit CISNET-projected data well (coefficient of variation [CV]-RMSE $\leq 15\%$). After incorporating smoking relapse, multiplying the CISNET-reported cessation rates for women/men by 7.75/7.25, to reflect the ratio of quit attempts to sustained abstinence, resulted in the best approximation to CISNET-reported smoking prevalence (CV-RMSE 2%/3%). In external validation using these new multipliers, STOP-generated cumulative mortality curves for 20-year-old current smokers and never smokers each had CV-RMSE $\leq 1\%$ compared to NHIS. In simulating those surveyed by NHIS in 1997, the STOP-projected

1
2
3 prevalence of current/former/never smokers annually (1998-2009) was similar to that reported by NHIS
4
5 (CV-RMSE 12%).
6
7
8
9

10 Conclusions: The STOP model, with relapse included, performed well when validated to US smoking
11 prevalence and mortality. STOP provides a flexible framework for policy-relevant analysis of tobacco and
12 nicotine product use.
13
14
15

16
17
18
19 Keywords: tobacco, nicotine, model, validation, calibration, relapse
20
21
22

23 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

24

- 25 • The STOP microsimulation model captures individual-level tobacco use behaviors and outcomes.
- 26 • The model is novel in incorporating relapse, a key factor in nicotine addiction.
- 27 • We validated STOP model results with those of another model and, in a partially dependent manner,
28 with empirical data.
- 29 • We validated with multiple outcomes, including smoking prevalence and mortality.
- 30 • This analysis did not account for some aspects of heterogeneity in tobacco use behaviors.
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

INTRODUCTION

In the US, tobacco smoking reduces life expectancy by over a decade and accounts for over \$200 billion in healthcare costs annually, approximately 9% of all healthcare costs in the country.[1,2] Though the prevalence of cigarette smoking among adults has decreased in the US, from 42% in 1965 to 14% in 2017, the decline has not been seen in all segments of society.[3,4] Meanwhile, tobacco treatment interventions, including behavioral therapy and pharmacotherapy, remain underutilized.[5]

Novel tobacco and nicotine products, including electronic cigarettes (e-cigs) and heated tobacco products, raise many new behavioral, clinical, and policy questions.[6,7] Trial- and cohort-based data to fully inform these questions will not be available for many years. In the meantime, a timely way to address these questions is via modeling.

Simulation models provide a critical complement to more traditional research approaches.[8–14]

Indeed, the Food and Drug Administration and the National Academies of Sciences, Engineering, and Medicine in the past year called for modeling studies to project the long-term effects, including both potential harms and benefits, of novel tobacco and nicotine products and regulatory policies to address them.[15,16] While multiple model-based studies of tobacco and nicotine products have been published,[17–25] most report aggregate trends, are focused at the population rather than individual level, and do not explicitly account for smoking relapse, a key component of the natural history and resource utilization of smoking cessation attempts. Our objective was to develop, calibrate, and validate a novel, individual-level microsimulation model that directly addresses the mechanics of smoking initiation, cessation, and relapse, and the associated clinical outcomes. The intended application of the model is to inform clinical and public health policy.

METHODS

Analytic overview

We developed a microsimulation model of tobacco- and nicotine-related behaviors, clinical outcomes, and treatments: the Simulating Tobacco and Nicotine Outcomes and Policy (STOP) model. In this analysis, we focused on cigarette smoking among US women and men to demonstrate that the STOP model, in simulating individuals' month-by-month smoking behaviors, can match historical smoking prevalence and mortality data. Our methods included: 1) performing internal validation to assess the model structure compared to another model; 2) incorporating smoking relapse and then calibrating smoking cessation probabilities to reflect the difference between a quit attempt and sustained abstinence; and 3) using our new relapse parameters, performing external validation to compare model outputs for mortality and for prevalence of current, former, and never smokers over time to empirical data from the National Health Interview Survey (NHIS) (table 1).

Table 1. Characteristics of internal and external validation analyses for a new microsimulation model of smoking behaviors and outcomes.

Analysis	STOP-generated output of interest	Comparator	Measure of goodness of fit
Internal validation ^a	1950 birth cohort prevalence of never, current, and former smokers, ages 0-70 years, by sex	CISNET-modeled 1950 birth cohort prevalence of never, current, and former smokers, ages 0-70 years, by sex	RMSE
External validation: mortality	Cumulative mortality by age, sex, and smoking status	Cumulative mortality and mortality rates of 1997-2009	MAPE and RMSE

NHIS respondents by age, sex,
and smoking status

External validation: smoking prevalence	Prevalence of never, current, and former smokers, annually, 1998-2009	NHIS never, current, and former smoking prevalence, annually, 1998-2009	RMSE
--------------------------------------------	-----------------------------------------------------------------------------	-------------------------------------------------------------------------------	------

STOP: Simulating Tobacco and Nicotine Outcomes and Policy model. CISNET: Cancer Intervention and Surveillance Monitoring Network. NHIS: National Health Interview Survey. RMSE: root-mean-square error. MAPE: mean absolute percentage error. ^aThe initial internal validation did not include smoking relapse. In the subsequent calibration step, we incorporated smoking relapse and calibrated cessation to achieve a good fit to the CISNET-modeled 1950 birth cohort prevalence of never, current, and former smokers.

Because there is no consensus criterion by which to compare model-generated results to surveillance data, expert guidance suggests choosing a criterion appropriate for the model structure and data sources.[26] Similar to methods used in validating other models, we chose root-mean-square error (RMSE, for cumulative risks and time-varying prevalence estimates) and mean absolute percentage error (MAPE, for mortality rates) to evaluate the goodness-of-fit between STOP model results and data sources.[26–32] We applied the coefficient of variation of RMSE (CV-RMSE) as a relative measure of error.

Model structure

The STOP model is an individual-level Monte Carlo microsimulation.[33,34] An individual enters the model with age and smoking status defined by random realizations from specified probability

1
2
3 distributions. The model follows a state-transition framework: individuals transition monthly through
4 various cigarette smoking states reflecting never, current, or former smoking status. Transitions
5 between these states depend on age- and sex-stratified monthly smoking initiation and cessation
6 probabilities. For ex-smokers there are monthly relapse probabilities (figure 1). Monthly mortality
7 probabilities depend on age, sex, and smoking status. Those who quit smoking retain the all-cause
8 mortality probabilities of current smokers until they have remained abstinent for a defined period of
9 time (e.g., five years), after which the mortality probabilities decline.[1,8,35]
10
11
12
13
14
15
16
17
18
19
20

21 Individuals are simulated in series: for each simulated person, the model tracks smoking behavioral
22 events (smoking initiation, quit attempt, relapse) and the duration spent in each smoking state. Upon an
23 individual's death, the next simulated person enters the model. Once a cohort large enough to attain
24 stable estimates has been simulated, summary statistics are calculated, including mean number of quit
25 attempts, life expectancy, and the monthly prevalence of never, current, and former smokers.
26
27
28
29
30
31
32
33
34

35 **Internal validation**

36 *Overview and outcome comparisons*

37
38 We conducted internal model validation (technical verification) by simulating the US population born in
39 1950, following them monthly until the year 2020, and then comparing STOP results to those from
40 modeling studies from the Cancer Intervention and Surveillance Modeling Network (CISNET) Lung
41 Working Group (table 1 and supplementary text).[26] We selected the 1950 birth cohort because
42 smoking prevalence in the US peaked in the 1960s, which was the smoking initiation period
43 (adolescence) for these individuals, and data collection frequency increased concurrently. We compared
44 STOP-generated results to CISNET-reported results for the prevalence of female and male current,
45 former, and never smokers over time.[35]
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We used CV-RMSE to assess the goodness of fit of the six sets of prevalence curves.[27,30] First, RMSE was calculated as the square root of the average of the squared difference between STOP-projected prevalence (among all simulated individuals who are alive) and CISNET-projected prevalence at each year of age. Then, we calculated CV-RMSE by dividing RMSE by mean modeled prevalence, representing the relative error.

Input parameters for initial internal validation

For the initial internal validation exercise, we used data from CISNET modeling studies, which were derived from NHIS and were stratified by birth cohort (table 2).[36,37] Specifically, we used CISNET age- and sex-stratified smoking initiation and cessation rates and smoking-stratified mortality rates among US women and men born in 1950, converting them to monthly probabilities. The CISNET smoking cessation rates reflected a direct transition from current smoker to former smoker after at least two years of sustained abstinence.[36] This initial internal validation exercise did not include smoking relapse.

Table 2. STOP model input parameters applied in validation exercises.

Variable	Internal validation	External validation:	External validation:
		mortality	smoking prevalence
Source	CISNET	NHIS 1997-2009	NHIS 1997
Baseline cohort characteristics			
Women/Men, % ^a	---	52/48	52/48
Initial age, mean, years (SD)	0	39.7 (21.4)	39.1 (20.7)

Minimum/maximum age, years	---	18/84	18/84
Initial prevalence of			
never/current/former	100/0/0	56/22/22	52/25/23
smokers ^b , %			
Years since cessation among			
former smokers, mean (SD)	---	15.6 (12.7)	14.4 (11.9)

Smoking behavior events

Monthly smoking initiation			
probability, by age and sex	0-0.0093		0-0.0063
Monthly smoking cessation			
probability, by age and sex	0-0.015		0-0.035

Clinical events

Monthly mortality probability ^c ,			
by age and sex, x 10 ⁻⁴			
Never smokers	0-12.8		0.4-95.2
Current smokers	0-34.6		0.4-136.1
Former smokers	Multiplier applied		0-111.5

Source: based on smoking studies or calibrated

Monthly relapse probability ^d			
(<i>t</i> = months since cessation)		$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	
Cessation rate multiplier			
(calibrated), women/men	7.75/7.25	7.75/7.25	7.5/7
Initiation rate multiplier			
(calibrated), women/men	---	---	0.9/1.0

1
2
3 Former smoker mortality

4 multiplier, applied to never

5 1.0-2.2

6 ---

7 ---

8 smoker mortality, by sex and

9 age at quit^e

10
11
12 STOP: Simulating Tobacco and Nicotine Outcomes and Policy. CISNET: Cancer Intervention and
13 Surveillance Modeling Network. NHIS: National Health Interview Survey. SD: standard deviation. The
14 numbers show model input parameters applied in internal validation (left), external validation of
15 mortality (center), and external validation of smoking prevalence (right).
16
17
18
19
20
21
22

23 ^aIn internal validation, we simulated cohorts of either all women or all men from birth. Thus, no
24 distributions of initial age are displayed.
25
26
27

28
29
30 ^bPrevalence of each smoking status displayed here is the mean over all strata, but in the model these
31 were stratified by 5-year age group and sex from ages 18 to 84.
32
33
34
35

36
37 ^cAdditional details about mortality data are in supplementary table 2.
38
39
40

41 ^dThis is based on relapse probabilities reported in smoking cessation intervention trials, focusing on
42 placebo arms.[38–41]
43
44
45

46
47
48 ^eCISNET-derived former smoker mortality rates are often lower than CISNET-derived never smoker
49 mortality rates for the 1950 birth cohort – a relationship with questionable face validity. We therefore
50 adapted former smoker mortality multipliers for the internal validation from Thun et al.[35]
51
52
53
54
55
56
57
58
59
60

Incorporating smoking relapse and calibrating cessation probabilities

A novel aspect of the STOP model is the explicit inclusion of smoking relapse. Relapse is critical to projecting both short-term and long-term impacts of smoking cessation interventions and novel tobacco and nicotine products.

The STOP model distinguishes between three states for those who have ever smoked: 1) Current Smoker; 2) Smoker who Recently Stopped; 3) Former Smoker (figure 1). This enables a differentiation between: 1) transient quit attempts: transition from the Current Smoker state to the Smoker who Recently Stopped state, with a relatively high rate of early relapse back to the Current Smoker state; and 2) sustained abstinence: transition from the Smoker who Recently Stopped state to the Former Smoker state, with a lower rate of later relapse back to the Current Smoker state.

Following the initial internal validation of the STOP model (without relapse), we added probabilities of smoking relapse and then recalibrated the model by adjusting the previously-applied smoking cessation probabilities. First, we modeled relapse as an exponential decay function of time since quit, such that the highest risk of relapse was in the first month after a quit attempt. The coefficient and time constant are based on relapse probabilities in smoking cessation trials (table 2).[38–41] Second, we calibrated the previously-applied cessation probabilities (derived from CISNET cessation data) by a multiplier to reflect: 1) a quit attempt rather than sustained abstinence; and 2) the higher likelihood of making a quit attempt rather than attaining sustained abstinence in a given month. This multiplier represents the average number of quit attempts, lasting at least one month, prior to attaining sustained abstinence. We compared our multipliers to published data on the average number of quit attempts required to attain sustained abstinence.[42] Our overall aim for this calibration step was to identify a STOP-generated

1
2
3 current smoker prevalence curve with an RMSE <0.01 compared to the CISNET model-generated current
4
5 smoker prevalence curve, in line with previously described methods.[30]
6
7
8
9

10 **External validation**

11 *Overview and outcome comparisons*

12
13 For external validation, we compared STOP model results to NHIS data rather than to the results of
14
15 another model (CISNET).[26,43] We accounted for smoking initiation, smoking cessation, and mortality.
16
17 Because NHIS data do not explicitly report relapse, we incorporated smoking relapse and the best-fitting
18
19 cessation multipliers found in the interval validation calibration step. We compared two outcomes:
20
21 mortality and smoking prevalence (table 1 and supplementary text).
22
23
24
25
26
27

28 First, to project and validate mortality outcomes, we simulated the population surveyed by NHIS from
29
30 1997 through 2009 (supplementary text). We used MAPE to compare STOP-generated mortality rates to
31
32 those derived from NHIS, stratified by age, sex, and smoking status. MAPE was the mean absolute value
33
34 of the percent difference between STOP and NHIS values. We also produced curves of cumulative
35
36 mortality from STOP-generated results and from NHIS data, stratified by sex and by current/never
37
38 smoking status. We compared the four sets of cumulative mortality curves by the RMSE and CV-RMSE
39
40 (STOP versus NHIS) from age 20 years until age 84 years (goal RMSE <0.01). We did not generate
41
42 cumulative mortality curves for former smokers in this step because mortality risks depend on age at
43
44 cessation, and this heterogeneous group would include people who quit smoking at a variety of
45
46 ages.[1,35]
47
48
49
50
51

52 Second, with those surveyed by NHIS in 1997 as the input cohort, we used the STOP model to project
53
54 the prevalence of current, former, and never smokers each year from 1998 to 2009. In a two-way
55
56
57
58
59
60

1
2
3 sensitivity analysis, we re-calibrated cessation multipliers along with initiation multipliers with the goal
4 of identifying multipliers that would minimize the CV-RMSE of STOP-reported current smoker
5 prevalence compared to NHIS current smoker prevalence. The initiation multipliers were applied to
6 smoking initiation rates for never smokers. We then compared the cessation multipliers from this step
7 with those from the internal validation calibration step.
8
9
10
11
12
13
14
15

16 *Input parameters*

17
18 The initial distributions of age, sex, and smoking status for the population simulated in the external
19 validation exercises came from two sources: aggregated 1997-2009 NHIS data for the mortality external
20 validation, and 1997 NHIS data for the smoking prevalence external validation (table 2 and
21 supplementary figure 1). We obtained NHIS data in aggregate for years 1997-2009 from the Integrated
22 Public Use Microdata Series.[44] These data provided initial distributions of smoking status and years of
23 abstinence for former smokers (to inform relapse risks). From these 1997-2009 NHIS data, we derived
24 age- and sex-specific smoking initiation and cessation rates using self-reported age at initiation and age
25 at cessation variables (supplementary table 1). As in our internal validation exercises, we converted the
26 cessation rates to quit attempt rates by incorporating relapse rates and cessation multipliers.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 The NHIS data include linked National Death Index (NDI) mortality outcomes through 2011 for
42 respondents for whom mortality data are available. We calculated mortality rates by age, sex, and
43 smoking status of the same NHIS respondents (supplementary table 1).
44
45
46
47
48
49

50 **Patient and public involvement**

51 We did not involve patients or the public in our work.
52
53
54
55
56
57
58
59
60

RESULTS

Internal validation

Initial internal validation, without relapse

The STOP-projected prevalence of current, former, and never smokers over time fit CISNET-projected data well for the 1950 birth cohort in the US (figure 2, blue line vs. red dotted line, RMSE <0.03, CV-RMSE 15%/7% for women/men). The STOP-estimated prevalence of current smokers at age 25 years, approaching peak prevalence for the 1950 birth cohort, was 40% for women and 54% for men, compared to CISNET estimates of 38% and 52%.

Incorporating smoking relapse and calibrating cessation probabilities

After incorporating smoking relapse, the prevalence of current smokers far exceeded that reported by the CISNET model, as expected since many of those who would have become former smokers reverted to being current smokers (figure 2, pink dashed lines). We then aimed to reflect all quit attempts rather than only transitions to sustained abstinence. In rough calibrations, we found that the optimal multiplier would be between 5 and 10 when applied to cessation rates from the previous step. In finer calibrations, we varied the multiplier across the range of 5 to 10 in increments of 0.25. We found that multiplying the CISNET-reported cessation rates by 7.75 for women and by 7.25 for men best approximated the CISNET-projected prevalence of current smokers, with RMSE 0.004/0.008 and CV-RMSE 2%/3% for women/men (figure 2, black lines). These multipliers fall within the published range of values for average number of quit attempts needed for successful abstinence.[42,45,46]

External validation

Mortality

In simulating the 1997-2009 NHIS population along with smoking relapse, we found that the age-, sex-, and smoking-stratified mortality rates generated by the STOP model were a good fit to those derived from NHIS (MAPE 7%, examples in supplementary table 2). The cumulative mortality curves for 20 year-old female and male current smokers and never smokers were similar between STOP projections and NHIS-derived data, with RMSE <0.01 and CV-RMSE ≤1% (figure 3). For those alive at age 20 years who continued to smoke until death, the STOP model predicted median life expectancy (counting years from birth) of 77.5 years for women and 72.5 years for men. These are similar to the median life expectancies for 30 year-old smokers reported by Jha et al. (also derived from NHIS data): 77 years for women and 72 years for men.[1]

Smoking prevalence

Using those surveyed by NHIS in 1997 as the input cohort, the STOP-projected prevalence of current, former, and never smokers each year from 1998 to 2009 was similar to that reported by NHIS, with overall RMSE 0.04 and CV-RMSE 12% for both women and men (ages 30-84 years combined; supplementary figure 2 shows results specifically for ages 40-44 years). Compared to NHIS, the STOP model slightly underpredicted never smoker prevalence and slightly overpredicted former smoker prevalence in later years. In the two-way sensitivity analysis, we found that cessation multipliers of 7.5/7.0 for women/men and initiation multipliers of 0.9/1.0 resulted in the best overall fit (lowest RMSE) of STOP-projected current smoker prevalence compared to that reported by NHIS (supplementary figure 3).

DISCUSSION

We developed, calibrated, and validated STOP, a novel microsimulation model of tobacco use behaviors and outcomes. Our initial model input parameters included smoking initiation and cessation and smoking-stratified mortality, and we demonstrated internal validity compared to the CISNET model. After incorporating relapse, we calibrated smoking cessation probabilities to reflect quit attempts rather than sustained abstinence. We then validated STOP model output with: 1) smoking prevalence over time reported by the CISNET model for US women and men born in 1950; 2) age-, sex-, and smoking-stratified mortality rates and cumulative mortality reported by the NHIS-NDI linked database for the years 1997-2009; and 3) prevalence of current, former, and never smokers by sex from 1998 to 2009 reported by NHIS, using 1997 NHIS-reported population characteristics as inputs.

The STOP model simulates individual-level tobacco use behaviors and associated clinical outcomes. Most existing tobacco models simulate at the population level or lack the capacity to consider smoking initiation and (non-sustained) quit attempts throughout a lifetime.[18,23–25,37,47,48] The individual-level details of STOP can be employed to simulate and compare behaviors and interventions. While this validation and calibration analysis focused on cigarette smoking because of the availability of historical data for comparisons, we intend to broaden the use of STOP to include e-cigs. Longitudinal cohort studies and clinical trials are examining the effects of e-cig use on tobacco smoking behaviors and clinical outcomes over long time horizons, but data are needed now to inform guidelines and policy around these novel products.[15,40,49,50] Results from multiple distinct, validated models can help motivate policy decisions, and consistency of policy recommendations across unique, independent models reinforces confidence in their recommendations.[51–55]

1
2
3 A novel aspect of the STOP model is the incorporation of smoking relapse, reflecting the understanding
4 of nicotine addiction and tobacco use as a chronic relapsing condition.[41,45,56–59] This key feature
5 enables an important distinction between a quit attempt and sustained abstinence. This distinction is
6 missing from most tobacco models and indeed from many epidemiologic studies of smoking and
7 smoking cessation, which consider the transition from “current” to “former” smoker to be an abrupt
8 one that results in sustained abstinence. Incorporating relapse required calibrating cessation rates by
9 applying multipliers. The cessation multipliers that provided the best fits to empirical data are in line
10 with published data regarding the number of quit attempts required before sustained abstinence is
11 achieved.[42,45,46] The slightly higher multiplier needed for women compared to men is consistent
12 with NHIS data showing that among ever smokers (current smokers plus former smokers) aged 60 years
13 and above, a greater proportion of women compared to men are former smokers.[44]

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 Many trials of smoking cessation interventions follow patients for a few months or up to one year, but
31 they do not report subsequent relapse. By including relapse, the STOP model can combine data from
32 short-term trials of smoking cessation interventions with data from natural history studies of smoking
33 and smoking cessation to project longer-term outcomes. In capturing changes in an individual’s smoking
34 behaviors over time, the STOP model can assess the efficacy of tobacco cessation interventions both in
35 the short-term, by the interventions promoting quit attempts, and in the long-term, by the interventions
36 reducing relapse and promoting sustained abstinence. The flexibility to integrate data from a variety of
37 sources is a strength of modeling analyses.

38
39
40
41
42
43
44
45
46
47
48
49
50 Going forward, we plan to use the STOP model to study contemporary rather than historical populations
51 and to predict future tobacco use. As no empirical data exist with which to validate model output of
52 future tobacco use, we validated STOP model output against historical populations. Most US historical
53
54
55
56
57
58
59
60

1
2
3 data on smoking prevalence and smoking-associated mortality are based at least in part on NHIS, the
4 oldest ongoing survey of smoking prevalence in the US.[1,4,60,61] We compared STOP model output to
5
6 CISNET model output, to NHIS itself, and to results from a study by Jha et al.,[1] all of which used NHIS
7
8 data. We demonstrated internal validity of STOP compared to CISNET model results when using CISNET
9
10 input parameters and then added relapse probabilities and cessation multipliers. We demonstrated
11
12 external validity, in a partially dependent manner, of STOP compared to NHIS data when using some
13
14 NHIS-derived input parameters plus the external relapse probabilities and cessation multipliers from our
15
16 internal validation. Though independent external validation sources are ideal, dependent sources can
17
18 still be useful, especially in this scenario where most of the available US historical smoking prevalence,
19
20 behavior, and mortality data are derived from NHIS.[26] Of note, in a two-way sensitivity analysis in
21
22 which we simultaneously varied the smoking initiation and cessation multipliers to achieve a close fit to
23
24 NHIS smoking prevalence data, the optimal cessation multipliers were very similar to those we found in
25
26 our internal validation calibration step, demonstrating the robustness of these multipliers across
27
28 different sets of assumptions.
29
30
31
32
33
34
35
36

37 In an external validation exercise, the STOP model projection for never smoker prevalence from 1998 to
38
39 2009 was slightly lower than that reported by NHIS, and the STOP model projection for former smoker
40
41 prevalence was slightly higher than NHIS data. In NHIS, former smokers were self-defined but on
42
43 average had been abstinent for over a decade. NHIS considered those who smoked “some days” to be
44
45 current smokers. STOP formally labels these people, who may have been abstinent from smoking for
46
47 only a very short duration, former smokers but assigns them the mortality risks of current smokers (until
48
49 a defined period of abstinence). Thus, one would expect the STOP model to predict a higher prevalence
50
51 of former smokers than NHIS, as seen in our results. Immigration could also account for some of the
52
53 difference between NHIS data and STOP model-generated results: immigrants were surveyed in NHIS
54
55
56
57
58
59
60

1
2
3 but our model analysis does not account for them. Smoking prevalence differs between the immigrant
4 and non-immigrant populations.[62,63]
5
6
7
8
9

10 The STOP model has features, and will have applications, not described in this analysis. We developed
11 the model to incorporate resource utilization. The STOP model can capture the healthcare costs
12 associated with being a current, former, or never smoker, as well as the costs of tobacco cessation
13 interventions. By incorporating the chronic relapsing nature of nicotine addiction, the STOP model can
14 account for the resources required for recurrent cessation interventions (e.g., restarting the same or a
15 different intervention after smoking relapse), an important consideration in cost-effectiveness and
16 policy analyses. Ultimately, we will use the STOP model to evaluate behavioral and clinical outcomes,
17 costs of care, and cost-effectiveness of tobacco cessation interventions, programs, and policies. An
18 overarching goal is to provide information that can inform decision makers – including clinicians, public
19 health officials, and policymakers – on cost-effective interventions that reduce the clinical and economic
20 burden of tobacco use. The model can eventually assess the impact of different financing options for
21 tobacco cessation interventions – for example, annual versus lifetime insurance coverage limits. The
22 flexibility in the STOP model structure will allow for analyses beyond US populations, including settings
23 where smoking-related behaviors and clinical outcomes may be different from those in the US.[64]
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 The STOP model has limitations. Its projections are limited by the degree of specificity of available data –
44 for example, age, sex, and birth year stratifications of smoking behavioral transitions. However,
45 probabilities of these transitions can be varied in sensitivity analysis. STOP does not include dynamics
46 such as the effects of one person's smoking on another person's smoking behaviors. Smoking is
47 associated with other factors not directly captured by STOP, including race, socioeconomic status,
48 mental illness, and other substance use, but different populations can be separately simulated in the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 model with input parameters specific to that population. There is considerable heterogeneity in smoking
4 behaviors, including cigarettes consumed per day and daily versus nondaily smoking. STOP enables
5 stratification by intensity of smoking, which can be used to represent amount or frequency of smoking.
6
7
8
9

10
11
12 In conclusion, STOP is a novel, individual-level microsimulation model that captures tobacco-related
13 behaviors – importantly including relapse – and outcomes with a goal of informing decision making
14 around tobacco cessation interventions and tobacco policy. We have demonstrated that the model is
15 well-calibrated and validated to historical cohorts. We plan to use the model for policy-relevant analysis
16 of contemporary patient-level and population-level care while reflecting real-life tobacco use and
17 cessation behaviors.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHOR CONTRIBUTIONS

Specific contributions are as follows:

KPR – study conception, study design, data analysis, data interpretation

AJB – study design, data analysis, data interpretation

DEL – study design, data interpretation

PT – data analysis, data interpretation

EPH – study design, data interpretation

TH – study conception, study design, data analysis

BO – study design

LY – data analysis, data interpretation

FMS – study design, data analysis, data interpretation

ADP – study design, data interpretation

KAF – study design, data interpretation

MCW – study design, data interpretation

NAR – study conception, study design, data interpretation

RPW – study conception, study design, data interpretation

KPR drafted the first version of the manuscript. All authors critically reviewed the manuscript for important intellectual content and approved the final submitted version.

COMPETING INTERESTS

NAR receives royalties from UpToDate, Inc., is a consultant for Achieve Life Sciences, and has been an unpaid consultant for Pfizer. All other authors report no competing interests.

SOURCES OF FUNDING

This work was supported by awards from the National Institute on Drug Abuse (K01 DA042687) and the National Heart, Lung, and Blood Institute (K01 HL123349) of the National Institutes of Health, and the Steve and Deborah Gorlin MGH Research Scholars Award. The funding sources had no role in the design, analysis, or interpretation of the study, the writing of the manuscript, or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Massachusetts General Hospital.

REFERENCES

- 1 Jha P, Ramasundarahettige C, Landsman V, *et al*. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;**368**:341–50. doi:10.1056/NEJMsa1211128
- 2 Xu X, Bishop EE, Kennedy SM, *et al*. Annual healthcare spending attributable to cigarette smoking: an update. *Am J Prev Med* 2015;**48**:326–33. doi:10.1016/j.amepre.2014.10.012
- 3 US Department of Health and Human Services. *The health consequences of smoking-50 years of progress: a report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
<https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html>
- 4 Wang TW, Asman K, Gentzke AS, *et al*. Tobacco product use among adults - United States, 2017. *MMWR Morb Mortal Wkly Rep* 2018;**67**:1225–32. doi:10.15585/mmwr.mm6744a2
- 5 Patel KK, Jones PG, Ellerbeck EF, *et al*. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry. *J Am Heart Assoc* 2018;**7**:e010076.
doi:10.1161/JAHA.118.010076
- 6 Office of the Commissioner, US Food and Drug Administration. FDA finalizes guidance for premarket tobacco product applications for electronic nicotine delivery systems as part of commitment to continuing a strong oversight of e-cigarettes. 11 Jun 2019. <http://www.fda.gov/news-events/press-announcements/fda-finalizes-guidance-premarket-tobacco-product-applications-electronic-nicotine-delivery-systems> (accessed 19 Jun 2019).
- 7 Office of the Commissioner, US Food and Drug Administration. FDA permits sale of IQOS Tobacco Heating System through premarket tobacco product application pathway. 30 Apr 2019.

- 1
2
3 <http://www.fda.gov/news-events/press-announcements/fda-permits-sale-iqos-tobacco-heating->
4 [system-through-premarket-tobacco-product-application-pathway](http://www.fda.gov/news-events/press-announcements/fda-permits-sale-iqos-tobacco-heating-) (accessed 19 Jun 2019).
5
6
7
8 Reddy KP, Parker RA, Losina E, *et al.* Impact of cigarette smoking and smoking cessation on life
9
10 expectancy among people with HIV: a US-based modeling study. *J Infect Dis* 2016;**214**:1672–81.
11
12 doi:10.1093/infdis/jiw430
13
14 Reddy KP, Kong CY, Hyle EP, *et al.* Lung cancer mortality associated with smoking and smoking
15
16 cessation among people living with HIV in the United States. *JAMA Intern Med* 2017;**177**:1613–21.
17
18 doi:10.1001/jamainternmed.2017.4349
19
20
21 10 Apelberg BJ, Feirman SP, Salazar E, *et al.* Potential public health effects of reducing nicotine levels in
22
23 cigarettes in the United States. *N Engl J Med* 2018;**378**:1725–33. doi:10.1056/NEJMs1714617
24
25
26 11 Walensky RP, Ross EL, Kumarasamy N, *et al.* Cost-effectiveness of HIV treatment as prevention in
27
28 serodiscordant couples. *N Engl J Med* 2013;**369**:1715–25. doi:10.1056/NEJMs1214720
29
30
31 12 Reddy KP, Gupta-Wright A, Fielding KL, *et al.* Cost-effectiveness of urine-based tuberculosis
32
33 screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. *Lancet Glob*
34
35 *Health* 2019;**7**:e200–8. doi:10.1016/S2214-109X(18)30436-4
36
37
38 13 Weinstein MC, O'Brien B, Hornberger J, *et al.* Principles of good practice for decision analytic
39
40 modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--
41
42 Modeling Studies. *Value Health* 2003;**6**:9–17.
43
44
45 14 Sanders GD, Neumann PJ, Basu A, *et al.* Recommendations for conduct, methodological practices,
46
47 and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and
48
49 Medicine. *JAMA* 2016;**316**:1093–103. doi:10.1001/jama.2016.12195
50
51
52 15 National Academies of Sciences, Engineering, and Medicine. *Public Health Consequences of E-*
53
54 *Cigarettes*. Washington, DC: The National Academies Press, 2018. doi:10.17226/24952
55
56
57
58
59
60

- 1
2
3 16 Office of Disease Prevention, National Institutes of Health. Tobacco regulatory research priorities.
4
5 <https://prevention.nih.gov/tobacco-regulatory-research/tobacco-regulatory-research-priorities>
6
7 (accessed 6 Jun 2019).
8
9
- 10 17 Levy DT, Cummings KM, Villanti AC, *et al.* A framework for evaluating the public health impact of e-
11
12 cigarettes and other vaporized nicotine products. *Addiction* 2017;**112**:8–17. doi:10.1111/add.13394
13
- 14 18 Levy DT, Yuan Z, Li Y, *et al.* A modeling approach to gauging the effects of nicotine vaping product
15
16 use on cessation from cigarettes: what do we know, what do we need to know? *Addiction* Published
17
18 Online First: 12 December 2018. doi:10.1111/add.14530
19
- 20 19 Warner KE, Mendez D. E-cigarettes: comparing the possible risks of increasing smoking initiation
21
22 with the potential benefits of increasing smoking cessation. *Nicotine Tob Res* 2019;**21**:41–7.
23
24 doi:10.1093/ntr/nty062
25
26
- 27 20 Cherng ST, Tam J, Christine P, *et al.* Modeling the effects of e-cigarettes on smoking behavior:
28
29 implications for future adult smoking prevalence. *Epidemiology* 2016;**27**:819–26.
30
31 doi:10.1097/EDE.0000000000000497
32
33
- 34 21 Kalkhoran S, Glantz SA. Modeling the health effects of expanding e-cigarette sales in the United
35
36 States and United Kingdom: a Monte Carlo analysis. *JAMA Intern Med* 2015;**175**:1671–80.
37
38 doi:10.1001/jamainternmed.2015.4209
39
40
- 41 22 Vugrin ED, Rostron BL, Verzi SJ, *et al.* Modeling the potential effects of new tobacco products and
42
43 policies: a dynamic population model for multiple product use and harm. *PLoS One*
44
45 2015;**10**:e0121008. doi:10.1371/journal.pone.0121008
46
47
- 48 23 Levy DT, Borland R, Lindblom EN, *et al.* Potential deaths averted in USA by replacing cigarettes with
49
50 e-cigarettes. *Tob Control* 2018;**27**:18–25. doi:10.1136/tobaccocontrol-2017-053759
51
- 52 24 Soneji SS, Sung H-Y, Primack BA, *et al.* Quantifying population-level health benefits and harms of e-
53
54 cigarette use in the United States. *PLoS One* 2018;**13**:e0193328. doi:10.1371/journal.pone.0193328
55
56
57
58
59

- 1
2
3 25 Levy DT, Borland R, Villanti AC, *et al.* The application of a decision-theoretic model to estimate the
4 public health impact of vaporized nicotine product initiation in the United States. *Nicotine Tob Res*
5 2017;**19**:149–59. doi:10.1093/ntr/ntw158
6
7
8
9
10 26 Eddy DM, Hollingworth W, Caro JJ, *et al.* Model transparency and validation: a report of the ISPOR-
11 SMDM Modeling Good Research Practices Task Force-7. *Med Decis Making* 2012;**32**:733–43.
12 doi:10.1177/0272989X12454579
13
14
15
16 27 Vanni T, Karnon J, Madan J, *et al.* Calibrating models in economic evaluation: a seven-step approach.
17 *Pharmacoeconomics* 2011;**29**:35–49. doi:10.2165/11584600-000000000-00000
18
19
20
21 28 Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative measures
22 of goodness of fit, parameter search strategies and convergence criteria. *Pharmacoeconomics*
23 2011;**29**:51–62. doi:10.2165/11584610-000000000-00000
24
25
26
27 29 Cevik M, Ergun MA, Stout NK, *et al.* Using active learning for speeding up calibration in simulation
28 models. *Med Decis Making* 2016;**36**:581–93. doi:10.1177/0272989X15611359
29
30
31
32 30 Ciaranello AL, Morris BL, Walensky RP, *et al.* Validation and calibration of a computer simulation
33 model of pediatric HIV infection. *PLoS One* 2013;**8**:e83389. doi:10.1371/journal.pone.0083389
34
35
36
37 31 Rydzak CE, Cotich KL, Sax PE, *et al.* Assessing the performance of a computer-based policy model of
38 HIV and AIDS. *PLoS One* 2010;**5**. doi:10.1371/journal.pone.0012647
39
40
41 32 Kazemian P, Wexler DJ, Fields NF, *et al.* Development and validation of PREDICT-DM: a new
42 microsimulation model to project and evaluate complications and treatments of type 2 diabetes
43 mellitus. *Diabetes Technol Ther* 2019;**21**:344–55. doi:10.1089/dia.2018.0393
44
45
46
47 33 Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation.
48 *Pharmacoeconomics* 2006;**24**:1043–53. doi:10.2165/00019053-200624110-00002
49
50
51
52 34 Rutter CM, Zaslavsky A, Feuer E. Dynamic microsimulation models for health outcomes: a review.
53 *Med Decis Making* 2011;**31**:10–8. doi:10.1177/0272989X10369005
54
55
56
57
58
59
60

- 1
2
3 35 Thun MJ, Carter BD, Feskanich D, *et al.* 50-year trends in smoking-related mortality in the United
4 States. *N Engl J Med* 2013;**368**:351–64. doi:10.1056/NEJMsa1211127
5
6
7 36 Holford TR, Levy DT, McKay LA, *et al.* Patterns of birth cohort-specific smoking histories, 1965-2009.
8 *Am J Prev Med* 2014;**46**:e31-37. doi:10.1016/j.amepre.2013.10.022
9
10
11 37 Holford TR, Meza R, Warner KE, *et al.* Tobacco control and the reduction in smoking-related
12 premature deaths in the United States, 1964-2012. *JAMA* 2014;**311**:164–71.
13
14
15
16
17
18
19 38 Tonstad S, Tønnesen P, Hajek P, *et al.* Effect of maintenance therapy with varenicline on smoking
20 cessation: a randomized controlled trial. *JAMA* 2006;**296**:64–71. doi:10.1001/jama.296.1.64
21
22
23 39 Brendryen H, Kraft P. Happy Ending: a randomized controlled trial of a digital multi-media smoking
24 cessation intervention. *Addiction* 2008;**103**:478–84. doi:10.1111/j.1360-0443.2007.02119.x
25
26
27 40 Bullen C, Howe C, Laugesen M, *et al.* Electronic cigarettes for smoking cessation: a randomised
28 controlled trial. *Lancet* 2013;**382**:1629–37. doi:10.1016/S0140-6736(13)61842-5
29
30
31
32 41 Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated
33 smokers. *Addiction* 2004;**99**:29–38.
34
35
36 42 Chaiton M, Diemert L, Cohen JE, *et al.* Estimating the number of quit attempts it takes to quit
37 smoking successfully in a longitudinal cohort of smokers. *BMJ Open* 2016;**6**:e011045.
38
39
40
41
42
43 43 Centers for Disease Control and Prevention. National Health Interview Survey. Adult tobacco use -
44 major changes. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_changes.htm (accessed 6 Jun
45
46
47
48
49 2019).
50 44 Blewett LA, Rivera Drew JA, Griffin R, *et al.* *IPUMS Health Surveys: National Health Interview Survey,*
51
52
53
54
55
56
57
58
59
60

- 1
2
3 45 Borland R, Partos TR, Yong H-H, *et al*. How much unsuccessful quitting activity is going on among
4
5 adult smokers? Data from the International Tobacco Control Four Country cohort survey. *Addiction*
6
7 2012;**107**:673–82. doi:10.1111/j.1360-0443.2011.03685.x
8
9
10 46 Jones JM. Smoking habits stable; most would like to quit. 18 Jul 2006. Gallup.com.
11
12 <https://news.gallup.com/poll/23791/Smoking-Habits-Stable-Most-Would-Like-Quit.aspx> (accessed 6
13
14 Jun 2019).
15
16 47 Warner KE, Mendez D. E-cigarettes: comparing the possible risks of increasing smoking initiation
17
18 with the potential benefits of increasing smoking cessation. *Nicotine Tob Res* 2019;**21**:41–7.
19
20 doi:10.1093/ntr/nty062
21
22
23 48 Feuer EJ, Levy DT, McCarthy WJ. Chapter 1: The impact of the reduction in tobacco smoking on U.S.
24
25 lung cancer mortality, 1975–2000: an introduction to the problem. *Risk Analysis* 2012;**32**:S6–13.
26
27 doi:10.1111/j.1539-6924.2011.01745.x
28
29
30 49 Hajek P, Phillips-Waller A, Przulj D, *et al*. A randomized trial of e-cigarettes versus nicotine-
31
32 replacement therapy. *N Engl J Med* 2019;**380**:629–37. doi:10.1056/NEJMoa1808779
33
34
35 50 Population Assessment of Tobacco and Health (PATH).
36
37 <https://pathstudyinfo.nih.gov/UI/HomeMobile.aspx> (accessed 6 Jun 2019).
38
39 51 Paltiel AD, Weinstein MC, Kimmel AD, *et al*. Expanded screening for HIV in the United States--an
40
41 analysis of cost-effectiveness. *N Engl J Med* 2005;**352**:586–95. doi:10.1056/NEJMsa042088
42
43
44 52 Sanders GD, Bayoumi AM, Sundaram V, *et al*. Cost-effectiveness of screening for HIV in the era of
45
46 highly active antiretroviral therapy. *N Engl J Med* 2005;**352**:570–85. doi:10.1056/NEJMsa042657
47
48
49 53 Dugdale CM, Ciaranello AL, Bekker L-G, *et al*. Risks and benefits of dolutegravir- and efavirenz-based
50
51 strategies for South African women with HIV of child-bearing potential: a modeling study. *Ann*
52
53 *Intern Med* Published Online First: 2 April 2019. doi:10.7326/M18-3358
54
55
56
57
58
59
60

- 1
2
3 54 Phillips AN, Venter F, Havlir D, *et al*. Risks and benefits of dolutegravir-based antiretroviral drug
4 regimens in sub-Saharan Africa: a modelling study. *Lancet HIV* 2019;**6**:e116–27. doi:10.1016/S2352-
5
6 3018(18)30317-5
7
8
9
10 55 Berry DA, Cronin KA, Plevritis SK, *et al*. Effect of screening and adjuvant therapy on mortality from
11 breast cancer. *N Engl J Med* 2005;**353**:1784–92. doi:10.1056/NEJMoa050518
12
13
14 56 Hughes JR, Solomon LJ, Naud S, *et al*. Natural history of attempts to stop smoking. *Nicotine Tob Res*
15 2014;**16**:1190–8. doi:10.1093/ntr/ntu052
16
17
18 57 Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: findings from
19 the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2009;**104**:2088–99.
20
21 doi:10.1111/j.1360-0443.2009.02732.x
22
23
24 58 Herd N, Borland R. The natural history of quitting smoking: findings from the International Tobacco
25 Control (ITC) Four Country Survey. *Addiction* 2009;**104**:2075–87. doi:10.1111/j.1360-
26
27 0443.2009.02731.x
28
29
30
31 59 National Institute on Drug Abuse. The science of drug use and addiction: the basics.
32
33 <https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics> (accessed
34
35 3 Jun 2019).
36
37
38 60 Babb S, Malarcher A, Schauer G, *et al*. Quitting smoking among adults - United States, 2000-2015.
39
40 *MMWR Morb Mortal Wkly Rep* 2017;**65**:1457–64. doi:10.15585/mmwr.mm6552a1
41
42
43 61 Garrett BE, Dube SR, Trosclair A, *et al*. Cigarette smoking - United States, 1965-2008. *MMWR Suppl*
44
45 2011;**60**:109–13.
46
47
48 62 Bosdriesz JR, Lichthart N, Witvliet MI, *et al*. Smoking prevalence among migrants in the US
49 compared to the US-born and the population in countries of origin. *PLoS One* 2013;**8**:e58654.
50
51 doi:10.1371/journal.pone.0058654
52
53
54
55
56
57
58
59
60

- 1
2
3 63 Pampel F, Khlal M, Bricard D, *et al*. Smoking among immigrant groups in the United States:
4 prevalence, education gradients, and male-to-female ratios. *Nicotine Tob Res* Published Online First:
5 13 February 2019. doi:10.1093/ntr/ntz022
6
7
8
9
10 64 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195
11 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study
12 2015. *Lancet* 2017;**389**:1885–906. doi:10.1016/S0140-6736(17)30819-X
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1. Overview of tobacco use states and transitions in Simulating Tobacco and Nicotine Outcomes and Policy (STOP) microsimulation model.

This is a simplified, stylized depiction of smoking states and transitions – for example, dimensions such as age and sex are not represented in the figure. The ovals represent possible cigarette smoking states or the deceased state. The arrows represent monthly transitions by which an individual can switch to a different state. The “Abstinence, sustained” transition is depicted by a dashed line because there is not a monthly probability of transition – instead, the transition occurs after an individual has spent a user-defined duration (e.g., one year) in the “Smoker who recently stopped” state. Numerical examples of the transition probabilities are in supplementary table 1.

Figure 2. Internal validation and calibration exercise: STOP-generated results and CISNET-generated results for current smoking prevalence over time for US people born in 1950.

STOP: Simulating Tobacco and Nicotine Outcomes and Policy model. CISNET: Cancer Intervention and Surveillance Modeling Network.

Panel A depicts women, Panel B depicts men. The red dotted line shows results from the CISNET model. The other three lines show STOP-generated results after each step of our parameterization and calibration process. The blue line includes parameterization of smoking initiation and cessation, but not relapse. The pink dashed line includes smoking relapse as based on published studies. The black line includes calibration of smoking cessation probabilities to reflect quit attempts and relapse before sustained abstinence.

1
2
3 **Figure 3. External validation: STOP model results and NHIS/NDI results for cumulative mortality of**
4 **current smokers and never smokers from age 20.**
5

6
7 STOP: Simulating Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.
8

9
10 NDI: National Death Index. CV-RMSE: coefficient of variation of root-mean-square error.
11

12
13
14 Panel A depicts women, Panel B depicts men. Within each panel, the STOP results and the NHIS data are
15
16 not easily distinguishable because they are essentially overlapping. Current smokers are those who
17
18 continue to smoke until death. NHIS was linked to NDI for mortality data.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1




Figure 2





Figure 3



A novel microsimulation model of tobacco use behaviors and outcomes**Supplement**

Krishna P. Reddy, Alexander J.B. Bulteel, Douglas E. Levy, Pamela Torola, Emily P. Hyle, Taige Hou,
Benjamin Osher, Liyang Yu, Fatma M. Shebl, A. David Paltiel, Kenneth A. Freedberg, Milton C. Weinstein,
Nancy A. Rigotti, Rochelle P. Walensky

Table of Contents

Methods: Supplementary Text	p. 2
References	p. 6
Supplementary Table 1	p. 7
Supplementary Table 2	p. 9
Supplementary Figure 1	p. 10
Supplementary Figure 2	p. 11
Supplementary Figure 3	p. 12

METHODS: SUPPLEMENTARY TEXT

CISNET Model

The Cancer Intervention and Surveillance Modeling Network (CISNET) is a collaboration of National Cancer Institute-supported investigators modeling the impact of interventions on population incidence and mortality of various types of cancer, including lung cancer. The Yale CISNET-Lung models, for subsequent analyses of cancer care interventions, used data from the National Health Interview Survey (NHIS) to generate detailed smoking initiation and cessation rates, stratified by birth year, age, and sex, and mortality rates, stratified by birth year, age, sex, and smoking status.[1,2]

National Health Interview Survey (NHIS)

NHIS is a yearly in-person questionnaire administered to the civilian noninstitutionalized population of the US which, since 1965, has collected information on individual smoking status. Since 1991, the smoking section of the NHIS has first queried “ever smoker” status – defined as having smoked at least 100 cigarettes in one’s lifetime – then asked ever smokers, “Do you NOW smoke cigarettes every day, some days or not at all?” which resulted in the classification of occasional smokers as current smokers, even though they initially may have said they did not smoke now. Regardless of response to the second question, participants were asked about the frequency of their smoking.[3]

Use of NHIS data in the Simulating Tobacco and Nicotine Outcomes and Policy (STOP) model

We downloaded NHIS and linked National Death Index (NDI) data from the Integrated Public Use Microdata Series (IPUMS) Health Surveys for the years 1997-2009.[4] We obtained basic demographic information, smoking status and behavioral variables, and death status/year of death reported through 2011. For all derivations below, we excluded those with unknown smoking or mortality status. Only

1
2
3 people 18 years of age or older were surveyed about tobacco use, and since ages 85+ years are
4
5 censored, we excluded those as well.
6
7
8
9

10 *External validation - mortality*

11
12 From the pooled 1997-2009 data, we used the IPUMS-recoded and -constructed survey weights
13
14 adjusting for differential representation in the smoking sub-sample and NDI follow-up. Because of the
15
16 NHIS sampling design, weights must be used so that the survey respondents can be collectively
17
18 expanded to represent the civilian noninstitutionalized population of the US. These weights represent a
19
20 surveyed individual's inverse probability of being included in both the survey supplement, which
21
22 contains questions about smoking, and the NHIS-NDI linked mortality files.
23
24
25
26
27

28 Smoking cessation inputs: We derived age- and sex-stratified cessation rates using the NHIS
29
30 variable that reported years since respondents (former smokers) quit smoking. We excluded
31
32 quit ages before age 16 years (due to perceived inconsistency of coding of the "time since quit"
33
34 variable – some entries implied negative quit age) and included quit ages through age 85 years.
35
36
37
38

39 Smoking initiation inputs: Similarly, we derived initiation rates, also age- and sex-stratified, using
40
41 the variable that reported years since the respondent (a current or former smoker) started to
42
43 smoke regularly. We used initiation rates from ages 6 to 61 years, the last age for which data are
44
45 consecutively available for both women and men.
46
47
48
49

50 Mortality inputs: We calculated mortality rates by age, sex, smoking status, and five-year age
51
52 group using the smoking status variable and NDI reporting through 2011. The rates were
53
54
55
56
57

1
2
3 calculated from a follow-up period beginning in the respondent's survey year and ending in
4
5 2011 or the year of her/his death, whichever came first.
6
7
8
9

10 Input cohort: We derived initial cohort characteristics for this analysis from the NHIS 1997-2009
11
12 pooled dataset: current, former and never smoking prevalence by five-year age group from age
13
14 <20 to 84 years; mean (standard deviation [SD]) age adjusted for bounding of the distribution;
15
16 sex distribution; and mean (SD) time since quit bounded by a minimum quit age of 16 years.
17
18
19
20

21 Output comparison: We compared STOP model output for mortality to NHIS/NDI-reported
22
23 mortality in the form of mortality rates and cumulative mortality from age 20 years.
24
25
26
27

28 *External validation – smoking prevalence*

29
30 From the NHIS 1997 data, using the same survey weights as above:
31
32
33

34 Smoking cessation, smoking initiation, and mortality inputs: We used the same cessation,
35
36 initiation, and mortality rate inputs as for the mortality validation.
37
38
39
40

41 Input cohort: We derived input cohort characteristics for this analysis from the 1997 NHIS data:
42
43 current, former, and never smoking prevalence by five-year age group from age <20 to 84 years;
44
45 mean (SD) age adjusted for bounding of the distribution; sex distribution; and mean (SD) time
46
47 since quit bounded by a minimum quit age of 16 years.
48
49
50
51
52
53
54
55
56
57

1
2
3 Output comparison: Starting with the 1997 NHIS respondents and following them each year
4
5 from 1998 to 2009, we compared STOP projections to NHIS data regarding prevalence of
6
7 current, former, and never smokers by five-year age group from age 30 to 84 years.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES IN SUPPLEMENT

- 1 Holford TR, Meza R, Warner KE, *et al.* Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. *JAMA* 2014;**311**:164–71. doi:10.1001/jama.2013.285112
- 2 Holford TR, Levy DT, McKay LA, *et al.* Patterns of birth cohort-specific smoking histories, 1965-2009. *Am J Prev Med* 2014;**46**:e31-37. doi:10.1016/j.amepre.2013.10.022
- 3 Centers for Disease Control and Prevention. National Health Interview Survey. Adult tobacco use - major changes. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_changes.htm (accessed 6 Jun 2019).
- 4 Blewett LA, Rivera Drew JA, Griffin R, *et al.* *IPUMS Health Surveys: National Health Interview Survey, Version 6.3 [dataset]*. Minneapolis, MN: IPUMS. <https://nhis.ipums.org> (accessed 20 Jun 2019).
- 5 Tonstad S, Tønnesen P, Hajek P, *et al.* Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA* 2006;**296**:64–71. doi:10.1001/jama.296.1.64
- 6 Brendryen H, Kraft P. Happy Ending: a randomized controlled trial of a digital multi-media smoking cessation intervention. *Addiction* 2008;**103**:478–84. doi:10.1111/j.1360-0443.2007.02119.x
- 7 Bullen C, Howe C, Laugesen M, *et al.* Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet* 2013;**382**:1629–37. doi:10.1016/S0140-6736(13)61842-5
- 8 Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;**99**:29–38.

Supplementary Table 1. Examples of transition probabilities in the simulation model.

Parameter	Value	Reference
Smoking initiation probability, monthly, by age and sex	0-0.0063	Derived from NHIS 1997-2009 data
Cessation probability, monthly, by age and sex	0-0.035	Derived from NHIS 1997-2009 data
Relapse probability, monthly, by time since cessation	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	[5–8]
Never smoker mortality probability, monthly, by age and sex, x 10 ⁻⁴	0.4-95.2	Derived from NHIS/NDI 1997-2009 data
Current smoker or recently quit smoker mortality probability, monthly, by age and sex, x 10 ⁻⁴	0.4-136.1	Derived from NHIS/NDI 1997-2009 data
Former smoker mortality probability, monthly, by age, sex, and time since cessation ^a , x 10 ⁻⁴	0-111.5	Derived from NHIS/NDI 1997-2009 data
Time to transition from “recently stopped” to “former smoker”	5 years	Assumption

NHIS: National Health Interview Survey. NDI: National Death Index. STOP: Simulating Tobacco and Nicotine Outcomes and Policy.

^aThese former smoker mortality probabilities were used only in the external validation exercises, comparing STOP model output to NHIS/NDI results. In internal validation comparing STOP model output

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

to the CISNET model results, we applied multipliers to never smoker mortality rates to derive former smoker mortality rates and then converted these to probabilities.

For peer review only


Supplementary Table 2. Selected age- and sex-specific annual mortality rates: STOP model output versus NHIS-derived mortality.

Women						
	Current smoker		Former smoker		Never smoker	
Age group, years	STOP	NHIS/NDI	STOP	NHIS/NDI	STOP	NHIS/NDI
40-44	0.0023	0.0023	0.0017	0.0015	0.0012	0.0012
50-54	0.0071	0.0071	0.0035	0.0029	0.0025	0.0025
60-64	0.0147	0.0146	0.0087	0.0079	0.0051	0.0051
Men						
	Current smoker		Former smoker		Never smoker	
Age group, years	STOP	NHIS/NDI	STOP	NHIS/NDI	STOP	NHIS/NDI
40-44	0.0031	0.0034	0.0028	0.0025	0.0018	0.0018
50-54	0.0094	0.0096	0.0059	0.0053	0.0042	0.0043
60-64	0.0233	0.0232	0.0114	0.0099	0.0067	0.0066

STOP: Simulating Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.

NDI: National Death Index.

1 **Supplementary Figure 1. Smoking status by age group and sex in 1997: STOP model inputs for the external validation exercise of smoking**
 2 **prevalence.**



3 STOP: Simulating Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.

4


5

6 Panel A depicts women; Panel B depicts men. For each age group, the prevalence of current, former, and never smokers is entered as STOP

7 model input. The external validation analysis of smoking prevalence, using weighted NHIS 1997 survey respondent data as inputs, projects

8 smoking prevalence annually from 1998 to 2009.


10 **Supplementary Figure 2. External validation: STOP model results and NHIS results for prevalence of current, former, and never smokers each**
 11 **year from 1998 to 2009.**



12
 13 STOP: Simulating Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey. NDI: National Death Index.

14
 15 Panel A depicts women, Panel B depicts men. The STOP model cohort had the age and smoking status distribution of the 1997 NHIS survey
 16 respondents (Supplementary Figure 1). The STOP-generated results reflect a microsimulation that included probabilities of smoking initiation,
 17 smoking cessation, smoking relapse, and mortality.

18 **Supplementary Figure 3. Two-way sensitivity analysis of smoking initiation and smoking cessation multipliers for external validation exercise.**



19

20 STOP: Simulating Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey. CV-RMSE: coefficient of variation of root-

21 mean-square error.

1
2
3 23 Panel A depicts women; Panel B depicts men. The multipliers were applied to the original cessation and initiation rates derived from pooled
4
5 24 1997-2009 NHIS data and used in the STOP model. The horizontal axis shows the multiplier applied to smoking initiation rates (subsequently
6
7
8 25 converted to probabilities) in the STOP model, and the vertical axis shows the multiplier applied to smoking cessation rates (subsequently
9
10 26 converted to probabilities). Colored cells represent the CV-RMSE of STOP model-generated versus NHIS-reported current smoking prevalence
11
12 27 among people ages 30-84 years from 1998 to 2009.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

BMJ Open

A novel microsimulation model of tobacco use behaviors and outcomes: calibration and validation in a US population

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032579.R1
Article Type:	Original research
Date Submitted by the Author:	03-Feb-2020
Complete List of Authors:	Reddy, Krishna; Massachusetts General Hospital, Medical Practice Evaluation Center Bulteel, Alexander; Massachusetts General Hospital, Medical Practice Evaluation Center Levy, Douglas; Massachusetts General Hospital Torola, Pamela; Massachusetts General Hospital, Medical Practice Evaluation Center Hyle, Emily; Massachusetts General Hospital, Medical Practice Evaluation Center Hou, Taige; Massachusetts General Hospital, Medical Practice Evaluation Center Osher, Benjamin; Massachusetts General Hospital, Medical Practice Evaluation Center Yu, Liyang; Massachusetts General Hospital, Medical Practice Evaluation Center Shebl, Fatma; Massachusetts General Hospital, Medical Practice Evaluation Center Paltiel, A David; Yale University School of Public Health Freedberg, Kenneth; Massachusetts General Hospital, Medical Practice Evaluation Center Weinstein, Milton ; Harvard University T H Chan School of Public Health Rigotti, Nancy; Massachusetts General Hospital Walensky, Rochelle; Massachusetts General Hospital, Medical Practice Evaluation Center
Primary Subject Heading:	Public health
Secondary Subject Heading:	Addiction, Epidemiology, Health policy, Health services research, Research methods
Keywords:	tobacco, nicotine, model, validation, calibration, relapse

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**A novel microsimulation model of tobacco use behaviors and outcomes:
calibration and validation in a US population**

Krishna P. Reddy^{1,2,3,7,*}, Alexander J.B. Bulteel¹, Douglas E. Levy^{2,4,7}, Pamela Torola¹, Emily P. Hyle^{1,6,7},
Taige Hou¹, Benjamin Osher¹, Liyang Yu¹, Fatma M. Shebl^{1,7}, A. David Paltiel⁸,
Kenneth A. Freedberg^{1,5,6,7,9}, Milton C. Weinstein^{7,9}, Nancy A. Rigotti^{2,5,7}, Rochelle P. Walensky^{1,5,6,7}

¹Medical Practice Evaluation Center, ²Tobacco Research and Treatment Center, ³Division of Pulmonary and Critical Care Medicine, ⁴Mongan Institute Health Policy Research Center, ⁵Division of General Internal Medicine, and ⁶Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

⁷Harvard Medical School, Boston, MA, USA

⁸Yale School of Public Health, New Haven, CT, USA

⁹Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA

*Corresponding author:

Krishna P. Reddy, MD, MS

Medical Practice Evaluation Center

Massachusetts General Hospital

100 Cambridge Street, Suite 1600

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Boston, MA 02114

USA

Email: kpreddy@mgh.harvard.edu

Phone: +1 617-726-1993

ABSTRACT WORD COUNT: 290

MAIN TEXT WORD COUNT: 3987

For peer review only

ABSTRACT

Background and Objective: Tobacco policymakers must consider how emerging products will change cigarette smoking behaviors and clinical outcomes. Our objective was to develop, calibrate, and validate a novel individual-level microsimulation model to project cigarette smoking behaviors and associated mortality risks. Unlike most tobacco models, our new model would explicitly include smoking relapse.

Methods: We developed the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model, in which individuals transition monthly between tobacco use states (current, former, or never) depending on rates of initiation, cessation, and relapse. Simulated individuals face tobacco use-stratified mortality risks. For US women and men, we conducted cross-validation with a Cancer Intervention and Surveillance Modeling Network (CISNET) model. We then incorporated smoking relapse and calibrated cessation rates to reflect the difference between a transient quit attempt and sustained abstinence. We performed external validation with the National Health Interview Survey (NHIS) and the linked National Death Index. Comparisons were based on root-mean-square error (RMSE).

Results: In cross-validation, STOP-generated projections of current/former/never smoking prevalence fit CISNET-projected data well (coefficient of variation [CV]-RMSE $\leq 15\%$). After incorporating smoking relapse, multiplying the CISNET-reported cessation rates for women/men by 7.75/7.25, to reflect the ratio of quit attempts to sustained abstinence, resulted in the best approximation to CISNET-reported smoking prevalence (CV-RMSE 2%/3%). In external validation using these new multipliers, STOP-generated cumulative mortality curves for 20-year-old current smokers and never smokers each had CV-RMSE $\leq 1\%$ compared to NHIS. In simulating those surveyed by NHIS in 1997, the STOP-projected prevalence of current/former/never smokers annually (1998-2009) was similar to that reported by NHIS (CV-RMSE 12%).

1
2
3
4
5 Conclusions: The STOP model, with relapse included, performed well when validated to US smoking
6 prevalence and mortality. STOP provides a flexible framework for policy-relevant analysis of tobacco and
7 nicotine product use.
8
9
10

11
12
13
14 Keywords: tobacco, nicotine, model, validation, calibration, relapse
15
16
17

18 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

19

- 20
21 • The STOP microsimulation model and our calibration and validation methods capture monthly
22 individual-level tobacco use behaviors and outcomes, including relapse, a key factor in nicotine
23 addiction.
24
25
- 26 • We validated STOP model results with those of another model and, in a partially dependent manner,
27 with empirical data.
28
29
- 30 • We validated with multiple outcomes, including smoking prevalence and mortality.
31
32
- 33 • This analysis did not account for some aspects of heterogeneity in tobacco use behaviors.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

INTRODUCTION

In the US, tobacco smoking reduces life expectancy by over a decade and accounts for over \$200 billion in healthcare costs annually, approximately 9% of all healthcare costs in the country.[1,2] Though the prevalence of cigarette smoking among adults has decreased in the US, from 42% in 1965 to 14% in 2018, the decline has not been seen in all segments of society.[3,4] Meanwhile, tobacco treatment interventions, including behavioral therapy and pharmacotherapy, remain underutilized.[5] Novel tobacco and nicotine products raise many new clinical and policy questions.[6,7] Trial- and cohort-based data to fully inform these questions will not be available for many years. In the meantime, a timely way to address them is via modeling.

Simulation models provide a critical complement to more traditional research approaches.[8–14] Indeed, the Food and Drug Administration and the National Academies of Sciences, Engineering, and Medicine recently called for modeling studies to project the long-term effects, including both potential harms and benefits, of novel tobacco and nicotine products and regulatory policies to address them.[15,16] While multiple model-based studies of tobacco and nicotine products have been published,[17–25] most report aggregate trends, are focused at the population rather than individual level, and do not explicitly account for smoking relapse, a key component of the natural history and resource utilization of smoking cessation attempts. A current challenge of projecting longer-term clinical and economic outcomes of short-term tobacco cessation studies lies in capturing the many smoking quit attempts and relapses.[26,27] A new model that intentionally examines relapse would extend trial results by projecting outcomes beyond the time horizon of trials, when many relapses occur. Our objective was to develop, calibrate, and validate a novel, individual-level microsimulation model that directly addresses the mechanics of smoking initiation, cessation, and relapse, and the associated clinical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

outcomes. The intended applications of the model include projecting the downstream impact of clinical and public health policy decisions and informing the design of tobacco treatment trials.

For peer review only

METHODS

Analytic overview

We developed a microsimulation model of tobacco- and nicotine-related behaviors, clinical outcomes, and treatments: the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model. In this analysis, we focused on cigarette smoking among US women and men to demonstrate that the STOP model, in simulating individuals' month-by-month smoking behaviors, can match historical smoking prevalence and mortality data. Our methods included: 1) performing internal validation to ensure the accuracy of the mathematical calculations; 2) conducting cross-validation with another model; 3) incorporating smoking relapse and then calibrating smoking cessation probabilities to reflect the difference between a quit attempt and sustained abstinence; and 4) using our new relapse parameters, performing external validation to compare model outputs for mortality and for prevalence of current, former, and never smokers over time to empirical data from the National Health Interview Survey (NHIS) (table 1).

Table 1. Characteristics of cross-validation and external validation analyses for a new microsimulation model of smoking behaviors and outcomes.

Analysis	STOP-generated output of interest	Comparator	Measure of goodness of fit
Cross-validation ^a	1950 birth cohort prevalence of never, current, and former smokers, ages 0-70 years, by sex	CISNET-modeled 1950 birth cohort prevalence of never, current, and former smokers, ages 0-70 years, by sex	RMSE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Mortality rates of 1997-2009

External validation: mortality	Cumulative mortality by age, sex, and smoking status	NHIS respondents by age, sex, and smoking status, and cumulative mortality	MAPE and RMSE
External validation: smoking prevalence	Prevalence of never, current, and former smokers, annually, 1998-2009	NHIS never, current, and former smoking prevalence, annually, 1998-2009	RMSE

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy model. CISNET: Cancer Intervention and Surveillance Monitoring Network. NHIS: National Health Interview Survey. RMSE: root-mean-square error. MAPE: mean absolute percentage error. ^aThe initial cross-validation did not include smoking relapse. In the subsequent calibration step, we incorporated smoking relapse and calibrated cessation to achieve a good fit to the CISNET-modeled 1950 birth cohort prevalence of never, current, and former smokers.

Because there is no consensus criterion by which to compare model-generated results to surveillance data, expert guidance suggests choosing a criterion appropriate for the model structure and data sources.[28] Similar to methods used in validating other models, we chose root-mean-square error (RMSE, for cumulative risks and time-varying prevalence estimates) and mean absolute percentage error (MAPE, for mortality rates) to evaluate the goodness-of-fit between STOP model results and data sources.[28–34] We applied the coefficient of variation of RMSE (CV-RMSE) as a relative measure of error.

Smoking definitions

Similar to NHIS and the Cancer Intervention and Surveillance Modeling Network (CISNET, which used NHIS data), we defined Never Smokers as those who had smoked <100 cigarettes in their lifetime.[35–37] Among others (ever smokers), NHIS defined current smokers as those who reported currently smoking every day or some days. NHIS considered ever smokers who reported no smoking at the time of interview to be former smokers, regardless of the duration of abstinence. CISNET considered former smokers to be those who had quit smoking at least two years prior to interview; those with a shorter period of abstinence were still considered current smokers.

To better distinguish relapse and mortality risks among those with short-term or long-term abstinence, the STOP model includes three states for those who have ever smoked: 1) Current Smoker; 2) Recent Quitter (short-term abstinence); 3) Former Smoker (long-term abstinence) (figure 1). This enables a differentiation between: 1) transient quit attempts: transition from the Current Smoker state to the Recent Quitter state, with a relatively high rate of early relapse back to the Current Smoker state; and 2) sustained abstinence: transition from the Recent Quitter state to the Former Smoker state, with a lower rate of later relapse back to the Current Smoker state.

STOP model structure

STOP is an individual-level Monte Carlo microsimulation.[38,39] An individual enters the model with age and smoking status defined by random realizations from specified probability distributions. STOP follows a state-transition framework: individuals transition monthly through various cigarette smoking states (figure 1). Transitions between these states depend on age- and sex-stratified monthly smoking initiation and cessation probabilities. Ex-smokers have monthly relapse probabilities (figure 1). Monthly mortality probabilities depend on age, sex, and smoking status. Those who quit smoking retain the all-

1
2
3 cause mortality probabilities of current smokers until maintaining abstinence for a defined period of
4
5 time, after which the mortality probabilities decline.[1,8,40]
6
7
8
9

10 Individuals are simulated in series: for each simulated person, the model tracks smoking behavioral
11
12 events (smoking initiation, quit attempt, relapse) and the duration spent in each smoking state. Upon an
13
14 individual's death, the next simulated person enters the model. Once a cohort large enough to attain
15
16 stable estimates has been simulated, summary statistics are calculated, including mean number of quit
17
18 attempts, life expectancy, and the monthly prevalence of never, current, and former smokers. For the
19
20 purpose of model output displays, those in the Recent Quitter state are considered "former smokers."
21
22
23 We use a constant simulated population size of one million to obtain stable estimates of these
24
25 "average" outcomes of interest.
26
27
28
29

30 **Internal validation**

31
32 We conducted internal model validation by comparing model outputs to expected results and by
33
34 conducting sensitivity analysis.
35
36
37
38

39 **Cross-validation**

40 *Overview and outcome comparisons*

41
42 We conducted cross-validation by simulating the US population born in 1950, following them monthly
43
44 until 2020, and then comparing STOP results to those from CISNET modeling studies (table 1 and
45
46 supplementary text).[28] We selected the 1950 birth cohort because smoking prevalence in the US
47
48 peaked in the 1960s, which was the smoking initiation period (adolescence) for these individuals, and
49
50 data collection frequency increased concurrently. We compared STOP-generated results to CISNET-
51
52
53
54
55
56
57
58
59
60

1
2
3 reported results for the prevalence of female and male current, former, and never smokers over
4
5 time.[40]
6
7
8
9

10 We used CV-RMSE to assess the goodness-of-fit of the six sets of prevalence curves.[29,32] First, RMSE
11
12 was calculated as the square root of the average of the squared difference between STOP-projected
13
14 prevalence and CISNET-projected prevalence at each year of age. Then, we calculated CV-RMSE by
15
16 dividing RMSE by mean modeled prevalence, representing the relative error.
17
18
19
20

21 *CISNET Model*

22
23 CISNET is a collaboration of National Cancer Institute-supported investigators modeling the impact of
24
25 interventions on population incidence and mortality of various types of cancer, including lung cancer.
26
27 The Yale CISNET-Lung models, for subsequent analyses of cancer care interventions, used data from
28
29 NHIS to generate detailed smoking initiation and cessation rates, stratified by birth year, age, and sex,
30
31 and mortality rates, stratified by birth year, age, sex, and smoking status.[37,41]
32
33
34
35
36

37 *Input parameters for initial cross-validation*

38
39 For the initial cross-validation exercise, we used data from CISNET modeling studies, which were derived
40
41 from NHIS through 2009 and were stratified by birth cohort (table 2).[37,41] Specifically, we used
42
43 CISNET age- and sex-stratified smoking initiation and cessation rates and smoking-stratified mortality
44
45 rates among US women and men born in 1950, converting them to monthly probabilities. The CISNET
46
47 smoking cessation rates reflected a direct transition from current smoker to former smoker after at least
48
49 two years of sustained abstinence.[41] This initial exercise used the same input parameters as CISNET
50
51 and did not include smoking relapse.
52
53
54
55
56
57
58
59
60

Table 2. STOP model input parameters applied in each validation exercise.

Input parameter	Cross-validation	External validation of mortality	External validation of smoking prevalence
Input parameters from CISNET (for cross-validation), NHIS 1997-2009 (for external validation of mortality), or NHIS 1997 (for external validation of smoking prevalence)			
Baseline cohort characteristics			
Women/Men, % ^a	---	52/48	52/48
Initial age, mean, years (SD)	0 (followed a birth cohort)	39.7 (21.4)	39.1 (20.7)
Minimum/maximum age, years	---	18/84	18/84
Initial prevalence of			
never/current/former smokers ^b , %	100/0/0	56/22/22	52/25/23
Years since cessation among former smokers, mean (SD)	---	15.6 (12.7)	14.4 (11.9)
Smoking behavior events			
Monthly smoking initiation probability, by age and sex	0-0.0093	0-0.0063	0-0.0063
Monthly smoking cessation probability, by age and sex	0-0.015	0-0.035	0-0.035
Mortality			

1	Monthly mortality probability ^c ,			
2	by age and sex, x 10 ⁻⁴			
3				
4	Never smokers	0-12.8	0.4-95.2	0.4-95.2
5				
6	Current smokers	0-34.6	0.4-136.1	0.4-136.1
7				
8		Multiplier applied		
9	Former smokers	(see last row)	0-111.5	0-111.5
10				
11				
12				
13				
14				
15				

Input parameters derived from smoking studies or from authors' calibration

16	Monthly relapse probability ^d			
17	(<i>t</i> = months since cessation)	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$
18				
19	Cessation rate multiplier			
20	(calibrated), women/men	7.75/7.25	7.75/7.25	7.5/7
21				
22	Initiation rate multiplier			
23	(calibrated), women/men	---	---	0.9/1.0
24				
25	Former smoker mortality			
26	multiplier, applied to never			
27	smoker mortality, by sex	1.0-2.2	---	---
28	and age at quit ^e			
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. CISNET: Cancer Intervention and Surveillance Modeling Network. NHIS: National Health Interview Survey. SD: standard deviation. The numbers show model input parameters applied in cross-validation (left column), external validation of mortality (center column), and external validation of smoking prevalence (right column).

^aIn cross-validation, we simulated cohorts of either all women or all men from birth. Thus, no distributions of initial age are displayed.

^bPrevalence of each smoking status displayed here is the mean over all strata, but in the model these were stratified by 5-year age group and sex from ages 18 to 84.

^cAdditional details about mortality data are in supplementary table 2.

^dThis is based on relapse probabilities reported in smoking cessation intervention trials, focusing on placebo arms.[42–45]

^eFor the 1950 birth cohort, some CISNET-derived former smoker mortality rates are lower than CISNET-derived never smoker mortality rates – a counterintuitive relationship otherwise unexplained. We therefore adapted former smoker mortality multipliers for the cross-validation from Thun et al.[40]

Incorporating smoking relapse and calibrating cessation probabilities

The STOP model specifically includes smoking relapse, critical to projecting both short-term and long-term impacts of smoking cessation interventions and novel tobacco and nicotine products.

Following the initial cross-validation of the STOP model (without relapse), we added smoking relapse probabilities and then recalibrated the model by adjusting the previously-applied smoking cessation probabilities. First, we modeled relapse as an exponential decay function of time since quit, such that the highest risk of relapse was in the first month after a quit attempt. The coefficient and time constant are based on relapse probabilities in smoking cessation trials (table 2).[42–45] Second, we calibrated the previously-applied cessation probabilities (derived from CISNET cessation data) by a multiplier to reflect:

1
2
3 1) a quit attempt rather than sustained abstinence; and 2) the higher likelihood of making a quit attempt
4 rather than attaining sustained abstinence in a given month. This multiplier represents the average
5 number of quit attempts, lasting at least one month, prior to attaining sustained abstinence. We
6 compared our multipliers to published data on the average number of quit attempts required to attain
7 sustained abstinence.[27] Our overall aim for this calibration step was to identify a STOP-generated
8 current smoker prevalence curve with an RMSE <0.01 compared to the CISNET model-generated current
9 smoker prevalence curve, similar to previously described methods.[32]

21 External validation

23 *Overview and outcome comparisons*

24 For external validation, we compared STOP model results to NHIS data.[28,36] We accounted for
25 smoking initiation, smoking cessation, and mortality. Because NHIS data do not explicitly report relapse,
26 we incorporated smoking relapse and the best-fitting cessation multipliers found in the cross-validation
27 calibration step. We compared two outcomes: mortality and smoking prevalence (table 1 and
28 supplementary text).

29
30 First, to project and validate mortality outcomes, we simulated the population surveyed by NHIS from
31 1997 through 2009 (supplementary text). To compare STOP-generated mortality rates to those derived
32 from NHIS – stratified by age, sex, and smoking status – we used MAPE, the mean absolute value of the
33 percent difference between STOP and NHIS values. We also produced curves of cumulative mortality
34 from STOP-generated results and from NHIS data, stratified by sex and by current/never smoking status.
35 These curves reflect 20-year-old current smokers who continue to smoke until death or 20-year-old
36 never smokers who never start smoking. We compared the four sets of cumulative mortality curves by
37 RMSE and CV-RMSE (STOP versus NHIS) from age 20 years until age 84 years (goal RMSE <0.01). We did
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

1
2
3 not generate mortality curves for 20-year-old former smokers because mortality risks for those who
4 stop smoking prior to age 20 are similar to those of never smokers.[1] Also, mortality risks depend on
5 age at cessation, and at older ages this heterogeneous group would include people who quit smoking at
6 a variety of ages.[1,40]
7
8
9
10

11
12
13
14 Second, with those surveyed by NHIS in 1997 as the input cohort, we used the STOP model to project
15 the prevalence of current, former, and never smokers each year from 1998 to 2009. In a two-way
16 sensitivity analysis, we re-calibrated cessation multipliers and initiation multipliers with the goal of
17 identifying multipliers that would minimize the CV-RMSE of STOP-reported current smoker prevalence
18 compared to NHIS current smoker prevalence. The initiation multipliers were applied to smoking
19 initiation rates for never smokers. We then compared the cessation multipliers from this step with those
20 from the cross-validation calibration step.
21
22
23
24
25
26
27
28
29
30

31 *Input parameters*

32
33 Initial distributions of age, sex, and smoking status for the population simulated in the external
34 validation exercises came from two sources: aggregated 1997-2009 NHIS data for the mortality external
35 validation, and 1997 NHIS data for the smoking prevalence external validation (table 2 and
36 supplementary figure 1). We obtained NHIS data in aggregate for years 1997-2009 from the Integrated
37 Public Use Microdata Series.[35] We used NHIS data through 2009 because those were the data used in
38 the CISNET studies, which were our comparator in cross-validation exercises.[37,41] These data
39 provided initial distributions of smoking status and years of abstinence for former smokers (to inform
40 relapse risks). From these 1997-2009 NHIS data, we derived age- and sex-specific smoking initiation and
41 cessation rates using self-reported age at initiation and age at cessation variables (supplementary table
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1). As in our cross-validation exercises, we converted the cessation rates to quit attempt rates by
4
5 incorporating relapse rates and cessation multipliers.
6
7

8
9
10 The NHIS data included linked National Death Index (NDI) mortality outcomes through 2011 for
11
12 respondents for whom mortality data were available. We calculated mortality rates by age, sex, and
13
14 smoking status of the same NHIS respondents (supplementary table 1).
15
16

17 18 19 **Patient and public involvement**

20
21 We did not involve patients or the public in our work.
22
23

24 25 **Ethics statement**

26
27 This study was approved by the Partners Human Research Committee (2019P001772).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Cross-validation

Initial cross-validation, without relapse

The STOP-projected prevalence of current, former, and never smokers over time fit CISNET-projected data well for the 1950 birth cohort in the US (figure 2, blue line vs. red dotted line, RMSE <0.03, CV-RMSE 15%/7% for women/men). The STOP-estimated prevalence of current smokers at age 25 years, approaching peak prevalence for the 1950 birth cohort, was 40% for women and 54% for men, compared to CISNET estimates of 38% and 52%.

Incorporating smoking relapse and calibrating cessation probabilities

After incorporating smoking relapse, the prevalence of current smokers far exceeded that reported by the CISNET model, as expected since many of those who would have become former smokers reverted to being current smokers (figure 2, pink dashed lines). We then aimed to reflect all quit attempts rather than only transitions to sustained abstinence. In rough calibrations, we found that the optimal multiplier would be between 5 and 10 when applied to cessation rates from the previous step. In finer calibrations, we varied the multiplier across the range of 5 to 10 in increments of 0.25. We found that multiplying the CISNET-reported cessation rates by 7.75 for women and by 7.25 for men best approximated the CISNET-projected prevalence of current smokers, with RMSE 0.004/0.008 and CV-RMSE 2%/3% for women/men (figure 2, black lines).

External validation

Mortality

In simulating the 1997-2009 NHIS population along with smoking relapse, we found that the age-, sex-, and smoking-stratified mortality rates generated by the STOP model were a good fit to those derived

1
2
3 from NHIS (MAPE 7%, examples in supplementary table 2). Cumulative mortality curves for 20 year-old
4 female and male current smokers and never smokers were similar between STOP projections and NHIS-
5 derived data, with RMSE <0.01 and CV-RMSE \leq 1% (figure 3). For 20-year-olds who continued to smoke
6 until death, the STOP model predicted median life expectancy (counting years from birth) of 77.5 years
7 for women and 72.5 years for men.
8
9
10
11
12
13
14
15

16 *Smoking prevalence*

17
18 Using those surveyed by NHIS in 1997 as the input cohort, the STOP-projected prevalence of current,
19 former, and never smokers each year from 1998 to 2009 was similar to that reported by NHIS, with
20 overall RMSE 0.04 and CV-RMSE 12% for both women and men (ages 30-84 years combined;
21 supplementary figure 2 shows results specifically for ages 40-44 years). Compared to NHIS, the STOP
22 model slightly underpredicted never smoker prevalence and slightly overpredicted former smoker
23 prevalence in later years. In the two-way sensitivity analysis, we found that cessation multipliers of
24 7.5/7.0 for women/men and initiation multipliers of 0.9/1.0 provided the best overall fit (lowest RMSE)
25 of STOP-projected current smoker prevalence compared to that reported by NHIS (supplementary figure
26 3).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

We developed, calibrated, and validated STOP, a novel microsimulation model of individual-level tobacco use behaviors and outcomes. Our initial model input parameters included smoking initiation and cessation and smoking-stratified mortality, and we demonstrated cross-validity compared to the CISNET model. After incorporating relapse, we calibrated smoking cessation probabilities to reflect quit attempts rather than sustained abstinence. We then validated STOP model output with: 1) smoking prevalence over time reported by the CISNET model for US women and men born in 1950; 2) age-, sex-, and smoking-stratified mortality rates and cumulative mortality reported by the NHIS-NDI linked database for the years 1997-2009; and 3) prevalence of current, former, and never smokers by sex from 1998 to 2009 reported by NHIS, using 1997 NHIS-reported population characteristics as inputs.

Most existing tobacco models simulate at the population level or lack the capacity to consider smoking initiation and (non-sustained) quit attempts throughout a lifetime.[18,23–25,37,46,47] The individual-level details of STOP can be employed to simulate and compare behaviors and interventions. While this calibration and validation analysis focused on cigarette smoking because of the availability of historical data for comparisons, we intend to broaden the use of STOP to include electronic cigarettes (e-cigs). Longitudinal cohort studies and clinical trials are examining the effects of e-cig use on tobacco smoking behaviors and clinical outcomes over long time horizons, but data are needed now to inform guidelines and policy around these novel products.[15,44,48,49] Results from multiple distinct, validated models can help motivate policy decisions, and consistency of policy recommendations across unique, independent models reinforces confidence in their recommendations.[50–54]

A novel aspect of the STOP model is the incorporation of smoking relapse on a monthly basis, reflecting the understanding of nicotine addiction as a chronic relapsing condition with rapid cycles between use

1
2
3 and cessation.[26,45,55–58] This key feature enables an important distinction between a quit attempt
4 and sustained abstinence. This distinction is missing from most tobacco models and indeed from many
5 epidemiologic studies of smoking and smoking cessation, which consider the transition from “current”
6 to “former” smoker to be an abrupt one that results in sustained abstinence. Incorporating relapse
7 required calibrating cessation rates by applying multipliers. The cessation multipliers that provided the
8 best fits to empirical data are in line with published data regarding the number of quit attempts
9 required before sustained abstinence is achieved.[27,55,59] The slightly higher multiplier needed for
10 women compared to men is consistent with NHIS data showing that among ever smokers (current
11 smokers plus former smokers) aged 60 years and above, a greater proportion of women compared to
12 men are former smokers.[35] Calibration of cessation rates may compensate for other inaccuracies in
13 model inputs or structure, though the pre-calibration (without relapse) STOP-generated results fit well
14 with those of CISNET.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Many trials of smoking cessation interventions follow patients for a few months or up to one year, but
33 they do not report subsequent relapse. By including relapse, the STOP model can combine data from
34 short-term trials of smoking cessation interventions with data from natural history studies of smoking
35 and smoking cessation to project longer-term outcomes including sustained abstinence. The flexibility to
36 integrate data from a variety of sources is a strength of modeling analyses.
37
38
39
40
41
42
43
44
45

46 Going forward, we plan to use the STOP model to study contemporary rather than historical populations
47 and to predict future tobacco use, while utilizing deterministic and probabilistic sensitivity analyses to
48 account for uncertainty in future behavioral transition probabilities and mortality probabilities.[60] As
49 no empirical data exist with which to validate model output of future tobacco use, we validated STOP
50 model output against historical populations. Most US historical data on smoking prevalence and
51
52
53
54
55
56
57
58
59
60

1
2
3 smoking-associated mortality are based at least in part on NHIS, the oldest ongoing survey of smoking
4 prevalence in the US.[1,61–63] We compared STOP model output to CISNET model output, to NHIS
5 itself, and to results from a study by Jha et al.,[1] all of which used NHIS data. We demonstrated cross-
6 validity of STOP compared to CISNET model results when using CISNET input parameters and then added
7 relapse probabilities and cessation multipliers. We demonstrated external validity, in a partially
8 dependent manner, of STOP compared to NHIS data when using some NHIS-derived input parameters
9 plus the external relapse probabilities and cessation multipliers from our cross-validation. Though
10 independent external validation sources are ideal, dependent sources can still be useful, especially in
11 this scenario where most of the available US historical smoking prevalence, behavior, and mortality data
12 are derived from NHIS.[28] Of note, in a two-way sensitivity analysis in which we simultaneously varied
13 the smoking initiation and cessation multipliers to achieve a close fit to NHIS smoking prevalence data,
14 the optimal cessation multipliers were very similar to those we found in our cross-validation calibration
15 step, demonstrating the robustness of these multipliers across different sets of assumptions.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 In an external validation exercise, the STOP model projection for never smoker prevalence from 1998 to
35 2009 was slightly lower than that reported by NHIS, and the STOP model projection for former smoker
36 prevalence was slightly higher than NHIS data. In NHIS, former smokers were self-defined but on
37 average had been abstinent for over a decade. NHIS considered those who smoked “some days” to be
38 current smokers, though some of them may have been in the midst of a short-duration quit attempt.
39 STOP model output formally labels these people, who may be in the Recent Quitter state, , former
40 smokers but assigns them the mortality risks of current smokers (until a defined period of abstinence).
41 STOP reflects monthly quitting and relapsing behaviors whereas NHIS is an annual cross-sectional
42 survey. Thus, one would expect the STOP model to report a higher prevalence of former smokers than
43 NHIS, as seen in our results. Immigration could also account for some of the difference between NHIS
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 data and STOP model-generated results: immigrants were surveyed in NHIS but our model analysis does
4 not account for them. Smoking prevalence differs between the immigrant and non-immigrant
5
6 populations.[64,65] On the other hand, STOP model-generated life expectancies were similar to the
7
8 median life expectancies for 30-year-old smokers reported by Jha et al. (also derived from NHIS data): 77
9
10 years for women and 72 years for men.[1]
11
12
13
14
15

16 The STOP model has features, and will have applications, not described in this analysis. We developed
17
18 the model to incorporate resource utilization. The STOP model can capture the healthcare costs
19
20 associated with being a current, former, or never smoker, as well as the costs of tobacco cessation
21
22 interventions. By incorporating the chronic relapsing nature of nicotine addiction, the STOP model can
23
24 account for the resources required for recurrent cessation interventions (e.g., restarting the same or a
25
26 different intervention after smoking relapse), an important consideration in cost-effectiveness and
27
28 policy analyses. Ultimately, we will use the STOP model to evaluate behavioral and clinical outcomes,
29
30 costs of care, and cost-effectiveness of tobacco cessation interventions, programs, and policies. An
31
32 overarching goal is to provide information that can inform decision makers – including clinicians, public
33
34 health officials, and policymakers – on cost-effective interventions that reduce the clinical and economic
35
36 burden of tobacco use. The model can eventually assess the impact of different financing options for
37
38 tobacco cessation interventions – for example, annual versus lifetime insurance coverage limits. The
39
40 STOP model’s flexibility will allow for analyses beyond US populations, including settings where
41
42 smoking-related behaviors and clinical outcomes may be different from those in the US.[66]
43
44
45
46
47
48
49

50 The STOP model has limitations. Its projections are limited by assumptions and the degree of specificity
51
52 of available data – for example, age, sex, and birth year stratifications of smoking behavioral transitions.
53
54 While we have aimed to calibrate and validate the model with the best available historical data, any use
55
56
57
58
59
60

1
2
3 of the model to project future outcomes should be approached with prudence. Calibration on historical
4 data is no panacea because of concerns of calibration drift. Nonetheless, input parameter values can be
5 varied in sensitivity analysis. STOP does not include dynamics such as the effects of one person's
6 smoking on another person's smoking behaviors. Smoking is associated with other factors not directly
7 captured by STOP, including race, socioeconomic status, mental illness, and other substance use, but
8 different populations can be separately simulated in the model with input parameters specific to that
9 population. There is considerable heterogeneity in smoking behaviors, including cigarettes consumed
10 per day and daily versus nondaily smoking. STOP enables stratification by intensity of smoking, which
11 can be used to represent amount or frequency of smoking.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 In conclusion, STOP is a novel, individual-level microsimulation model that captures tobacco-related
26 behaviors – importantly including relapse – and outcomes with a goal of informing decision making
27 around tobacco cessation interventions and tobacco policy. We have demonstrated that the model is
28 well-calibrated and validated to another model and to historical cohorts. We plan to use the model for
29 policy-relevant analysis of contemporary patient-level and population-level care while reflecting real-life
30 tobacco use and cessation behaviors.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHOR CONTRIBUTIONS

Specific contributions are as follows:

KPR – study conception, study design, data analysis, data interpretation

AJB – study design, data analysis, data interpretation

DEL – study design, data interpretation

PT – data analysis, data interpretation

EPH – study design, data interpretation

TH – study conception, study design, data analysis

BO – study design

LY – data analysis, data interpretation

FMS – study design, data analysis, data interpretation

ADP – study design, data interpretation

KAF – study design, data interpretation

MCW – study design, data interpretation

NAR – study conception, study design, data interpretation

RPW – study conception, study design, data interpretation

KPR drafted the first version of the manuscript. All authors critically reviewed the manuscript for important intellectual content and approved the final submitted version.

COMPETING INTERESTS

NAR receives royalties from UpToDate, Inc., is a consultant for Achieve Life Sciences, and has been an unpaid consultant for Pfizer. All other authors report no competing interests.

SOURCES OF FUNDING

This work was supported by awards from the National Institute on Drug Abuse (K01 DA042687) and the National Heart, Lung, and Blood Institute (K01 HL123349) of the National Institutes of Health, and the Steve and Deborah Gorlin MGH Research Scholars Award. The funding sources had no role in the design, analysis, or interpretation of the study, the writing of the manuscript, or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Massachusetts General Hospital.

DATA STATEMENT

Data used to parameterize the model are publicly available at <https://resources.cisnet.cancer.gov/projects> and at <https://nhis.ipums.org/nhis>.

REFERENCES

- 1 Jha P, Ramasundarahettige C, Landsman V, *et al*. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;**368**:341–50. doi:10.1056/NEJMsa1211128
- 2 Xu X, Bishop EE, Kennedy SM, *et al*. Annual healthcare spending attributable to cigarette smoking: an update. *Am J Prev Med* 2015;**48**:326–33. doi:10.1016/j.amepre.2014.10.012
- 3 US Department of Health and Human Services. *The health consequences of smoking-50 years of progress: a report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014. <https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html>
- 4 Creamer MR, Wang TW, Babb S, *et al*. Tobacco product use and cessation indicators among adults - United States, 2018. *MMWR Morb Mortal Wkly Rep* 2019;**68**:1013–9. doi:10.15585/mmwr.mm6845a2
- 5 Patel KK, Jones PG, Ellerbeck EF, *et al*. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry. *J Am Heart Assoc* 2018;**7**:e010076. doi:10.1161/JAHA.118.010076
- 6 Office of the Commissioner, US Food and Drug Administration. FDA finalizes guidance for premarket tobacco product applications for electronic nicotine delivery systems as part of commitment to continuing a strong oversight of e-cigarettes. 11 Jun 2019. <http://www.fda.gov/news-events/press-announcements/fda-finalizes-guidance-premarket-tobacco-product-applications-electronic-nicotine-delivery-systems> (accessed 9 Jan 2020).
- 7 Office of the Commissioner, US Food and Drug Administration. FDA permits sale of IQOS Tobacco Heating System through premarket tobacco product application pathway. 30 Apr 2019. <http://www.fda.gov/news-events/press-announcements/fda-permits-sale-iqos-tobacco-heating-system-through-premarket-tobacco-product-application-pathway> (accessed 9 Jan 2020).
- 8 Reddy KP, Parker RA, Losina E, *et al*. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. *J Infect Dis* 2016;**214**:1672–81. doi:10.1093/infdis/jiw430
- 9 Reddy KP, Kong CY, Hyle EP, *et al*. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. *JAMA Intern Med* 2017;**177**:1613–21. doi:10.1001/jamainternmed.2017.4349
- 10 Apelberg BJ, Feirman SP, Salazar E, *et al*. Potential public health effects of reducing nicotine levels in cigarettes in the United States. *N Engl J Med* 2018;**378**:1725–33. doi:10.1056/NEJMsr1714617
- 11 Walensky RP, Ross EL, Kumarasamy N, *et al*. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med* 2013;**369**:1715–25. doi:10.1056/NEJMsa1214720

- 1
2
3 12 Reddy KP, Gupta-Wright A, Fielding KL, *et al.* Cost-effectiveness of urine-based tuberculosis
4 screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. *Lancet Glob*
5 *Health* 2019;**7**:e200–8. doi:10.1016/S2214-109X(18)30436-4
6
7 13 Weinstein MC, O'Brien B, Hornberger J, *et al.* Principles of good practice for decision analytic
8 modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--
9 Modeling Studies. *Value Health* 2003;**6**:9–17. doi:10.1046/j.1524-4733.2003.00234.x
10
11 14 Sanders GD, Neumann PJ, Basu A, *et al.* Recommendations for conduct, methodological practices,
12 and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and
13 Medicine. *JAMA* 2016;**316**:1093–103. doi:10.1001/jama.2016.12195
14
15 15 National Academies of Sciences, Engineering, and Medicine. *Public Health Consequences of E-*
16 *Cigarettes*. Washington, DC: The National Academies Press 2018. doi:10.17226/24952
17
18 16 Office of Disease Prevention, National Institutes of Health. Tobacco regulatory research priorities.
19 <https://prevention.nih.gov/tobacco-regulatory-research/tobacco-regulatory-research-priorities>
20 (accessed 9 Jan 2020).
21
22 17 Levy DT, Cummings KM, Villanti AC, *et al.* A framework for evaluating the public health impact of e-
23 cigarettes and other vaporized nicotine products. *Addiction* 2017;**112**:8–17. doi:10.1111/add.13394
24
25 18 Levy DT, Yuan Z, Li Y, *et al.* A modeling approach to gauging the effects of nicotine vaping product
26 use on cessation from cigarettes: what do we know, what do we need to know? *Addiction* 2019;**114**
27 **Suppl 1**:86–96. doi:10.1111/add.14530
28
29 19 Warner KE, Mendez D. E-cigarettes: comparing the possible risks of increasing smoking initiation
30 with the potential benefits of increasing smoking cessation. *Nicotine Tob Res* 2019;**21**:41–7.
31 doi:10.1093/ntr/nty062
32
33 20 Cherng ST, Tam J, Christine P, *et al.* Modeling the effects of e-cigarettes on smoking behavior:
34 implications for future adult smoking prevalence. *Epidemiology* 2016;**27**:819–26.
35 doi:10.1097/EDE.0000000000000497
36
37 21 Kalkhoran S, Glantz SA. Modeling the health effects of expanding e-cigarette sales in the United
38 States and United Kingdom: a Monte Carlo analysis. *JAMA Intern Med* 2015;**175**:1671–80.
39 doi:10.1001/jamainternmed.2015.4209
40
41 22 Vugrin ED, Rostron BL, Verzi SJ, *et al.* Modeling the potential effects of new tobacco products and
42 policies: a dynamic population model for multiple product use and harm. *PLoS One*
43 2015;**10**:e0121008. doi:10.1371/journal.pone.0121008
44
45 23 Levy DT, Borland R, Lindblom EN, *et al.* Potential deaths averted in USA by replacing cigarettes with
46 e-cigarettes. *Tob Control* 2018;**27**:18–25. doi:10.1136/tobaccocontrol-2017-053759
47
48 24 Soneji SS, Sung H-Y, Primack BA, *et al.* Quantifying population-level health benefits and harms of e-
49 cigarette use in the United States. *PLoS One* 2018;**13**:e0193328. doi:10.1371/journal.pone.0193328
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 25 Levy DT, Borland R, Villanti AC, *et al.* The application of a decision-theoretic model to estimate the
4 public health impact of vaporized nicotine product initiation in the United States. *Nicotine Tob Res*
5 2017;**19**:149–59. doi:10.1093/ntr/ntw158
6
7 26 Hughes JR, Solomon LJ, Naud S, *et al.* Natural history of attempts to stop smoking. *Nicotine Tob Res*
8 2014;**16**:1190–8. doi:10.1093/ntr/ntu052
9
10 27 Chaiton M, Diemert L, Cohen JE, *et al.* Estimating the number of quit attempts it takes to quit
11 smoking successfully in a longitudinal cohort of smokers. *BMJ Open* 2016;**6**:e011045.
12 doi:10.1136/bmjopen-2016-011045
13
14 28 Eddy DM, Hollingworth W, Caro JJ, *et al.* Model transparency and validation: a report of the ISPOR-
15 SMDM Modeling Good Research Practices Task Force-7. *Med Decis Making* 2012;**32**:733–43.
16 doi:10.1177/0272989X12454579
17
18 29 Vanni T, Karnon J, Madan J, *et al.* Calibrating models in economic evaluation: a seven-step approach.
19 *Pharmacoeconomics* 2011;**29**:35–49. doi:10.2165/11584600-000000000-00000
20
21 30 Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative measures
22 of goodness of fit, parameter search strategies and convergence criteria. *Pharmacoeconomics*
23 2011;**29**:51–62. doi:10.2165/11584610-000000000-00000
24
25 31 Cevik M, Ergun MA, Stout NK, *et al.* Using active learning for speeding up calibration in simulation
26 models. *Med Decis Making* 2016;**36**:581–93. doi:10.1177/0272989X15611359
27
28 32 Ciaranello AL, Morris BL, Walensky RP, *et al.* Validation and calibration of a computer simulation
29 model of pediatric HIV infection. *PLoS One* 2013;**8**:e83389. doi:10.1371/journal.pone.0083389
30
31 33 Rydzak CE, Cotich KL, Sax PE, *et al.* Assessing the performance of a computer-based policy model of
32 HIV and AIDS. *PLoS One* 2010;**5**. doi:10.1371/journal.pone.0012647
33
34 34 Kazemian P, Wexler DJ, Fields NF, *et al.* Development and validation of PREDICT-DM: a new
35 microsimulation model to project and evaluate complications and treatments of type 2 diabetes
36 mellitus. *Diabetes Technol Ther* 2019;**21**:344–55. doi:10.1089/dia.2018.0393
37
38 35 Blewett LA, Rivera Drew JA, Griffin R, *et al.* *IPUMS Health Surveys: National Health Interview Survey,*
39 *Version 6.3 [dataset]*. Minneapolis, MN: IPUMS. <https://nhis.ipums.org> (accessed 9 Jan 2020).
40
41 36 Centers for Disease Control and Prevention. National Health Interview Survey. Adult tobacco use -
42 major changes. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_changes.htm (accessed 9 Jan
43 2020).
44
45 37 Holford TR, Meza R, Warner KE, *et al.* Tobacco control and the reduction in smoking-related
46 premature deaths in the United States, 1964-2012. *JAMA* 2014;**311**:164–71.
47 doi:10.1001/jama.2013.285112
48
49 38 Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation.
50 *Pharmacoeconomics* 2006;**24**:1043–53. doi:10.2165/00019053-200624110-00002
51
52
53
54
55
56
57
58
59
60

- 1
2
3 39 Rutter CM, Zaslavsky A, Feuer E. Dynamic microsimulation models for health outcomes: a review.
4 *Med Decis Making* 2011;**31**:10–8. doi:10.1177/0272989X10369005
5
6 40 Thun MJ, Carter BD, Feskanich D, *et al.* 50-year trends in smoking-related mortality in the United
7 States. *N Engl J Med* 2013;**368**:351–64. doi:10.1056/NEJMsa1211127
8
9 41 Holford TR, Levy DT, McKay LA, *et al.* Patterns of birth cohort-specific smoking histories, 1965-2009.
10 *Am J Prev Med* 2014;**46**:e31-37. doi:10.1016/j.amepre.2013.10.022
11
12 42 Tonstad S, Tønnesen P, Hajek P, *et al.* Effect of maintenance therapy with varenicline on smoking
13 cessation: a randomized controlled trial. *JAMA* 2006;**296**:64–71. doi:10.1001/jama.296.1.64
14
15 43 Brendryen H, Kraft P. Happy Ending: a randomized controlled trial of a digital multi-media smoking
16 cessation intervention. *Addiction* 2008;**103**:478–84. doi:10.1111/j.1360-0443.2007.02119.x
17
18 44 Bullen C, Howe C, Laugesen M, *et al.* Electronic cigarettes for smoking cessation: a randomised
19 controlled trial. *Lancet* 2013;**382**:1629–37. doi:10.1016/S0140-6736(13)61842-5
20
21 45 Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated
22 smokers. *Addiction* 2004;**99**:29–38. doi:10.1111/j.1360-0443.2004.00540.x
23
24 46 Warner KE, Mendez D. E-cigarettes: comparing the possible risks of increasing smoking initiation
25 with the potential benefits of increasing smoking cessation. *Nicotine Tob Res* 2019;**21**:41–7.
26 doi:10.1093/ntr/nty062
27
28 47 Feuer EJ, Levy DT, McCarthy WJ. Chapter 1: The impact of the reduction in tobacco smoking on U.S.
29 lung cancer mortality, 1975–2000: an introduction to the problem. *Risk Analysis* 2012;**32**:S6–13.
30 doi:10.1111/j.1539-6924.2011.01745.x
31
32 48 Hajek P, Phillips-Waller A, Przulj D, *et al.* A randomized trial of e-cigarettes versus nicotine-
33 replacement therapy. *N Engl J Med* 2019;**380**:629–37. doi:10.1056/NEJMoa1808779
34
35 49 Population Assessment of Tobacco and Health (PATH).
36 <https://pathstudyinfo.nih.gov/UI/HomeMobile.aspx> (accessed 9 Jan 2020).
37
38 50 Paltiel AD, Weinstein MC, Kimmel AD, *et al.* Expanded screening for HIV in the United States--an
39 analysis of cost-effectiveness. *N Engl J Med* 2005;**352**:586–95. doi:10.1056/NEJMsa042088
40
41 51 Sanders GD, Bayoumi AM, Sundaram V, *et al.* Cost-effectiveness of screening for HIV in the era of
42 highly active antiretroviral therapy. *N Engl J Med* 2005;**352**:570–85. doi:10.1056/NEJMsa042657
43
44 52 Dugdale CM, Ciaranello AL, Bekker L-G, *et al.* Risks and benefits of dolutegravir- and efavirenz-based
45 strategies for South African women with HIV of child-bearing potential: a modeling study. *Ann*
46 *Intern Med* 2019;**170**:614–25. doi:10.7326/M18-3358
47
48 53 Phillips AN, Venter F, Havlir D, *et al.* Risks and benefits of dolutegravir-based antiretroviral drug
49 regimens in sub-Saharan Africa: a modelling study. *Lancet HIV* 2019;**6**:e116–27. doi:10.1016/S2352-
50 3018(18)30317-5
51
52
53
54
55
56
57
58
59
60

- 1
2
3 54 Berry DA, Cronin KA, Plevritis SK, *et al.* Effect of screening and adjuvant therapy on mortality from
4 breast cancer. *N Engl J Med* 2005;**353**:1784–92. doi:10.1056/NEJMoa050518
5
- 6 55 Borland R, Partos TR, Yong H-H, *et al.* How much unsuccessful quitting activity is going on among
7 adult smokers? Data from the International Tobacco Control Four Country cohort survey. *Addiction*
8 2012;**107**:673–82. doi:10.1111/j.1360-0443.2011.03685.x
9
- 10 56 Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: findings from
11 the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2009;**104**:2088–99.
12 doi:10.1111/j.1360-0443.2009.02732.x
13
- 14 57 Herd N, Borland R. The natural history of quitting smoking: findings from the International Tobacco
15 Control (ITC) Four Country Survey. *Addiction* 2009;**104**:2075–87. doi:10.1111/j.1360-
16 0443.2009.02731.x
17
- 18 58 National Institute on Drug Abuse. The science of drug use and addiction: the basics.
19 <https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics> (accessed
20 9 Jan 2020).
21
- 22 59 Jones JM. Smoking habits stable; most would like to quit. 18 Jul 2006. Gallup.com.
23 <https://news.gallup.com/poll/23791/Smoking-Habits-Stable-Most-Would-Like-Quit.aspx> (accessed 9
24 Jan 2020).
25
- 26 60 Briggs AH, Weinstein MC, Fenwick EAL, *et al.* Model parameter estimation and uncertainty analysis:
27 a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. *Med*
28 *Decis Making* 2012;**32**:722–32. doi:10.1177/0272989X12458348
29
- 30 61 Wang TW, Asman K, Gentzke AS, *et al.* Tobacco product use among adults - United States, 2017.
31 *MMWR Morb Mortal Wkly Rep* 2018;**67**:1225–32. doi:10.15585/mmwr.mm6744a2
32
- 33 62 Babb S, Malarcher A, Schauer G, *et al.* Quitting smoking among adults - United States, 2000-2015.
34 *MMWR Morb Mortal Wkly Rep* 2017;**65**:1457–64. doi:10.15585/mmwr.mm6552a1
35
- 36 63 Garrett BE, Dube SR, Trosclair A, *et al.* Cigarette smoking - United States, 1965-2008. *MMWR Suppl*
37 2011;**60**:109–13.
38
- 39 64 Bosdriesz JR, Lichthart N, Witvliet MI, *et al.* Smoking prevalence among migrants in the US
40 compared to the US-born and the population in countries of origin. *PLoS One* 2013;**8**:e58654.
41 doi:10.1371/journal.pone.0058654
42
- 43 65 Pampel F, Khat M, Bricard D, *et al.* Smoking among immigrant groups in the United States:
44 prevalence, education gradients, and male-to-female ratios. *Nicotine Tob Res* Published Online First:
45 13 February 2019. doi:10.1093/ntr/ntz022
46
- 47 66 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195
48 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study
49 2015. *Lancet* 2017;**389**:1885–906. doi:10.1016/S0140-6736(17)30819-X
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1. Overview of tobacco use states and transitions in Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) microsimulation model.

This is a simplified, stylized depiction of smoking states and transitions – for example, dimensions such as age and sex are not represented in the figure. The ovals represent possible cigarette smoking states or the deceased state. The arrows represent monthly transitions by which an individual can switch to a different state. The “Abstinence, sustained” transition is depicted by a dashed line because there is not a monthly probability of transition – instead, the transition occurs after an individual has spent a user-defined duration (e.g., one year) in the “Recent Quitter” state. Numerical examples of the transition probabilities are in supplementary table 1.

Figure 2. Cross-validation and calibration exercise: STOP-generated results and CISNET-generated results for current smoking prevalence over time for US people born in 1950.

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy model. CISNET: Cancer Intervention and Surveillance Modeling Network.

Panel A depicts women, Panel B depicts men. The red dotted line shows results from the CISNET model. The other three lines show STOP-generated results after each step of our parameterization and calibration process. The blue line includes parameterization of smoking initiation and cessation, but not relapse. The pink dashed line includes smoking relapse as based on published studies. The black line includes calibration of smoking cessation probabilities to reflect quit attempts and relapse before sustained abstinence.


1
2
3 **Figure 3. External validation: STOP model results and NHIS/NDI results for cumulative mortality of**
4 **current smokers and never smokers from age 20.**
5

6
7 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.

8
9
10 NDI: National Death Index. CV-RMSE: coefficient of variation of root-mean-square error.



11
12
13
14 Panel A depicts women, Panel B depicts men. Within each panel, the STOP results and the NHIS data are
15
16 not easily distinguishable because they are essentially overlapping. Current smokers are those who
17
18 continue to smoke until death. NHIS was linked to NDI for mortality data.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Figure 2




- 1. No relapse
- 2. Relapse incorporated, uncalibrated cessation
- 3. Relapse incorporated, calibrated cessation
- CISNET 1950


- 1. No relapse
- 2. Relapse incorporated, uncalibrated cessation
- 3. Relapse incorporated, calibrated cessation
- CISNET 1950

Figure 3

A
 Cumulative mortality by smoking status, women



B
 Cumulative mortality by smoking status, men



**A novel microsimulation model of tobacco use behaviors and outcomes:
calibration and validation in a US population**

Supplement

Krishna P. Reddy, Alexander J.B. Bulteel, Douglas E. Levy, Pamela Torola, Emily P. Hyle, Taige Hou,
Benjamin Osher, Liyang Yu, Fatma M. Shebl, A. David Paltiel, Kenneth A. Freedberg, Milton C. Weinstein,
Nancy A. Rigotti, Rochelle P. Walensky

Table of Contents

Methods: Supplementary Text	p. 2
References	p. 6
Supplementary Table 1	p. 7
Supplementary Table 2	p. 9
Supplementary Figure 1	p. 10
Supplementary Figure 2	p. 11
Supplementary Figure 3	p. 12

METHODS: SUPPLEMENTARY TEXT

National Health Interview Survey (NHIS)

NHIS is a yearly in-person questionnaire administered to the civilian noninstitutionalized population of the US which, since 1965, has collected information on individual smoking status. Since 1991, the smoking section of the NHIS has first queried “ever smoker” status – defined as having smoked at least 100 cigarettes in one’s lifetime – then asked ever smokers, “Do you NOW smoke cigarettes every day, some days or not at all?” which resulted in the classification of occasional smokers as current smokers, even though they initially may have said they did not smoke now. Regardless of response to the second question, participants were asked about the frequency of their smoking.[1]

Use of NHIS data in the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model

We downloaded NHIS and linked National Death Index (NDI) data from the Integrated Public Use Microdata Series (IPUMS) Health Surveys for the years 1997-2009.[2] We obtained basic demographic information, smoking status and behavioral variables, and death status/year of death reported through 2011. For all derivations below, we excluded those with unknown smoking or mortality status. Only people 18 years of age or older were surveyed about tobacco use, and since ages 85+ years are censored, we excluded those as well.

External validation - mortality

From the pooled 1997-2009 data, we used the IPUMS-recoded and -constructed survey weights adjusting for differential representation in the smoking sub-sample and NDI follow-up. Because of the NHIS sampling design, weights must be used so that the survey respondents can be collectively expanded to represent the civilian noninstitutionalized population of the US. These weights represent a

1
2
3 surveyed individual's inverse probability of being included in both the survey supplement, which
4
5 contains questions about smoking, and the NHIS-NDI linked mortality files.
6
7
8
9

10 Smoking cessation inputs: We derived age- and sex-stratified cessation rates using the NHIS
11 variable that reported years since respondents (former smokers) quit smoking. We excluded
12 quit ages before age 16 years (due to perceived inconsistency of coding of the "time since quit"
13 variable – some entries implied negative quit age) and included quit ages through age 85 years.
14
15
16
17
18
19
20

21 Smoking initiation inputs: Similarly, we derived initiation rates, also age- and sex-stratified, using
22 the variable that reported years since the respondent (a current or former smoker) started to
23 smoke regularly. We used initiation rates from ages 6 to 61 years, the last age for which data are
24 consecutively available for both women and men.
25
26
27
28
29
30
31

32 Mortality inputs: We calculated mortality rates by age, sex, smoking status, and five-year age
33 group using the smoking status variable and NDI reporting through 2011. The rates were
34 calculated from a follow-up period beginning in the respondent's survey year and ending in
35 2011 or the year of her/his death, whichever came first. Because smoking behavior data were
36 collected only at baseline in NHIS and not again at the time of death, there may have been some
37 misclassification of smoking status (e.g., someone who was a current smoker at the time of NHIS
38 assessment may have subsequently quit and later died but was still considered a current
39 smoker). However, all-cause mortality rates do not significantly decrease until a few years after
40 cessation, and we considered those who had quit smoking to have similar mortality risks to
41 current smokers until five years of abstinence. This reflects contemporary studies in which
42 former smokers were defined as those who had not smoked in the previous five years and data
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 from large US cohort studies that indicate that the all-cause mortality risk in men who quit
4
5 smoking does not fall below that of current smokers until five years of abstinence.[3,4]
6
7
8
9

10 Input cohort: We derived initial cohort characteristics for this analysis from the NHIS 1997-2009
11
12 pooled dataset: current, former and never smoking prevalence by five-year age group from age
13
14 <20 to 84 years; mean (standard deviation [SD]) age adjusted for bounding of the distribution;
15
16 sex distribution; and mean (SD) time since quit bounded by a minimum quit age of 16 years.
17
18
19
20

21 Output comparison: We compared STOP model output for mortality to NHIS/NDI-reported
22
23 mortality in the form of mortality rates and cumulative mortality from age 20 years.
24
25
26
27

28 *External validation – smoking prevalence*

29
30 From the NHIS 1997 data, using the same survey weights as above:
31
32
33

34 Smoking cessation, smoking initiation, and mortality inputs: We used the same cessation,
35
36 initiation, and mortality rate inputs as for the mortality validation.
37
38
39
40

41 Input cohort: We derived input cohort characteristics for this analysis from the 1997 NHIS data:
42
43 current, former, and never smoking prevalence by five-year age group from age <20 to 84 years;
44
45 mean (SD) age adjusted for bounding of the distribution; sex distribution; and mean (SD) time
46
47 since quit bounded by a minimum quit age of 16 years.
48
49
50
51
52
53
54
55
56
57

1
2
3 Output comparison: Starting with the 1997 NHIS respondents and following them each year
4
5 from 1998 to 2009, we compared STOP projections to NHIS data regarding prevalence of
6
7 current, former, and never smokers by five-year age group from age 30 to 84 years.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES IN SUPPLEMENT

- 1 Centers for Disease Control and Prevention. National Health Interview Survey. Adult tobacco use - major changes. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_changes.htm (accessed 9 Jan 2020).
- 2 Blewett LA, Rivera Drew JA, Griffin R, et al. *IPUMS Health Surveys: National Health Interview Survey, Version 6.3 [dataset]*. Minneapolis, MN: IPUMS. <https://nhis.ipums.org> (accessed 9 Jan 2020).
- 3 Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med* 2013;**368**:351–64. doi:10.1056/NEJMsa1211127
- 4 Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;**368**:341–50. doi:10.1056/NEJMsa1211128
- 5 Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA* 2006;**296**:64–71. doi:10.1001/jama.296.1.64
- 6 Brendryen H, Kraft P. Happy Ending: a randomized controlled trial of a digital multi-media smoking cessation intervention. *Addiction* 2008;**103**:478–84. doi:10.1111/j.1360-0443.2007.02119.x
- 7 Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet* 2013;**382**:1629–37. doi:10.1016/S0140-6736(13)61842-5
- 8 Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;**99**:29–38. doi:10.1111/j.1360-0443.2004.00540.x

Supplementary Table 1. Examples of transition probabilities in the simulation model.

Parameter	Value	Reference
Smoking initiation probability, monthly, by age and sex	0-0.0063	Derived from NHIS 1997-2009 data
Cessation probability, monthly, by age and sex	0-0.035	Derived from NHIS 1997-2009 data
Relapse probability, monthly, by time since cessation	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	[5–8]
Never Smoker mortality probability, monthly, by age and sex, x 10 ⁻⁴	0.4-95.2	Derived from NHIS/NDI 1997-2009 data
Current Smoker or Recent Quitter mortality probability, monthly, by age and sex, x 10 ⁻⁴	0.4-136.1	Derived from NHIS/NDI 1997-2009 data
Former Smoker mortality probability, monthly, by age, sex, and time since cessation ^a , x 10 ⁻⁴	0-111.5	Derived from NHIS/NDI 1997-2009 data
Time to transition from Recent Quitter to Former Smoker	5 years ^b	Assumption, [3,4]

NHIS: National Health Interview Survey. NDI: National Death Index. STOP: Simulation of Tobacco and Nicotine Outcomes and Policy.

^aThese former smoker mortality probabilities were used only in the external validation exercises, comparing STOP model output to NHIS/NDI results. In cross-validation comparing STOP model output to

1
2
3 the CISNET model results, we applied multipliers to never smoker mortality rates to derive former
4
5 smoker mortality rates and then converted these to probabilities.
6
7
8
9

10 ^bThis five-year abstinence period was based on data showing mortality risks by years since smoking
11
12 cessation.[3,4] We performed an analysis in which we assumed that mortality risks decreased to
13
14 “Former Smoker” levels immediately upon quitting smoking, but the model-generated results were not
15
16 a better fit to NHIS data (results not shown).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Table 2. Selected age- and sex-specific annual mortality rates: STOP model output versus NHIS-derived mortality.


Women						
	Current Smoker		Former Smoker		Never Smoker	
Age group, years	STOP	NHIS/NDI	STOP	NHIS/NDI	STOP	NHIS/NDI
40-44	0.0023	0.0023	0.0017	0.0015	0.0012	0.0012
50-54	0.0071	0.0071	0.0035	0.0029	0.0025	0.0025
60-64	0.0147	0.0146	0.0087	0.0079	0.0051	0.0051
Men						
	Current Smoker		Former Smoker		Never Smoker	
Age group, years	STOP	NHIS/NDI	STOP	NHIS/NDI	STOP	NHIS/NDI
40-44	0.0031	0.0034	0.0028	0.0025	0.0018	0.0018
50-54	0.0094	0.0096	0.0059	0.0053	0.0042	0.0043
60-64	0.0233	0.0232	0.0114	0.0099	0.0067	0.0066

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.


NDI: National Death Index.

1 **Supplementary Figure 1. Smoking status by age group and sex in 1997: STOP model inputs for the external validation exercise of smoking**
 2 **prevalence.**

A




B



3
 4 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.
 5
 6 Panel A depicts women; Panel B depicts men. For each age group, the prevalence of current, former, and never smokers is entered as STOP
 7 model input. The external validation analysis of smoking prevalence, using weighted NHIS 1997 survey respondent data as inputs, projects
 8 smoking prevalence annually from 1998 to 2009.


10 **Supplementary Figure 2. External validation: STOP model results and NHIS results for prevalence of current, former, and never smokers each**
 11 **year from 1998 to 2009.**



12
 13 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey. NDI: National Death Index.

14
 15 Panel A depicts women, Panel B depicts men. The STOP model cohort had the age and smoking status distribution of the 1997 NHIS survey
 16 respondents (Supplementary Figure 1). The STOP-generated results reflect a microsimulation that included probabilities of smoking initiation,
 17 smoking cessation, smoking relapse, and mortality.

18 **Supplementary Figure 3. Two-way sensitivity analysis of smoking initiation and smoking cessation multipliers for external validation exercise.**



19

20 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey. CV-RMSE: coefficient of variation of

21 root-mean-square error.

1
2
3 23 Panel A depicts women; Panel B depicts men. The multipliers were applied to the original cessation and initiation rates derived from pooled
4
5 24 1997-2009 NHIS data and used in the STOP model. The horizontal axis shows the multiplier applied to smoking initiation rates (subsequently
6
7
8 25 converted to probabilities) in the STOP model, and the vertical axis shows the multiplier applied to smoking cessation rates (subsequently
9
10 26 converted to probabilities). Colored cells represent the CV-RMSE of STOP model-generated versus NHIS-reported current smoking prevalence
11
12 27 among people ages 30-84 years from 1998 to 2009.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

BMJ Open

A novel microsimulation model of tobacco use behaviors and outcomes: calibration and validation in a US population

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032579.R2
Article Type:	Original research
Date Submitted by the Author:	02-Mar-2020
Complete List of Authors:	Reddy, Krishna; Massachusetts General Hospital, Medical Practice Evaluation Center Bulteel, Alexander; Massachusetts General Hospital, Medical Practice Evaluation Center Levy, Douglas; Massachusetts General Hospital Torola, Pamela; Massachusetts General Hospital, Medical Practice Evaluation Center Hyle, Emily; Massachusetts General Hospital, Medical Practice Evaluation Center Hou, Taige; Massachusetts General Hospital, Medical Practice Evaluation Center Osher, Benjamin; Massachusetts General Hospital, Medical Practice Evaluation Center Yu, Liyang; Massachusetts General Hospital, Medical Practice Evaluation Center Shebl, Fatma; Massachusetts General Hospital, Medical Practice Evaluation Center Paltiel, A David; Yale University School of Public Health Freedberg, Kenneth; Massachusetts General Hospital, Medical Practice Evaluation Center Weinstein, Milton ; Harvard University T H Chan School of Public Health Rigotti, Nancy; Massachusetts General Hospital Walensky, Rochelle; Massachusetts General Hospital, Medical Practice Evaluation Center
Primary Subject Heading:	Public health
Secondary Subject Heading:	Addiction, Epidemiology, Health policy, Health services research, Research methods
Keywords:	tobacco, nicotine, model, validation, calibration, relapse

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A novel microsimulation model of tobacco use behaviors and outcomes:**
4
5 **calibration and validation in a US population**
6
7
8
9

10 Krishna P. Reddy^{1,2,3,7,*}, Alexander J.B. Bulteel¹, Douglas E. Levy^{2,4,7}, Pamela Torola¹, Emily P. Hyle^{1,6,7},
11
12 Taige Hou¹, Benjamin Osher¹, Liyang Yu¹, Fatma M. Shebl^{1,7}, A. David Paltiel⁸,
13
14 Kenneth A. Freedberg^{1,5,6,7,9}, Milton C. Weinstein^{7,9}, Nancy A. Rigotti^{2,5,7}, Rochelle P. Walensky^{1,5,6,7}
15

16
17
18 ¹Medical Practice Evaluation Center, ²Tobacco Research and Treatment Center, ³Division of Pulmonary
19 and Critical Care Medicine, ⁴Mongan Institute Health Policy Research Center, ⁵Division of General
20
21 Internal Medicine, and ⁶Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA,
22
23
24
25 USA
26

27
28
29
30 ⁷Harvard Medical School, Boston, MA, USA
31

32
33
34 ⁸Yale School of Public Health, New Haven, CT, USA
35

36
37
38
39 ⁹Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA,
40
41 USA
42

43
44
45 *Corresponding author:
46

47 Krishna P. Reddy, MD, MS
48

49 Medical Practice Evaluation Center
50

51 Massachusetts General Hospital
52

53 100 Cambridge Street, Suite 1600
54
55
56
57

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Boston, MA 02114

USA

Email: kpreddy@mgh.harvard.edu

Phone: +1 617-726-1993

ABSTRACT WORD COUNT: 300

MAIN TEXT WORD COUNT: 3998

For peer review only

ABSTRACT

Background and Objective: Simulation models can project effects of tobacco use and cessation and inform tobacco control policies. Most existing tobacco models do not explicitly include relapse, a key component of the natural history of tobacco use. Our objective was to develop, calibrate, and validate a novel individual-level microsimulation model that would explicitly include smoking relapse and project cigarette smoking behaviors and associated mortality risks.

Methods: We developed the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model, in which individuals transition monthly between tobacco use states (current/former/never) depending on rates of initiation, cessation, and relapse. Simulated individuals face tobacco use-stratified mortality risks. For US women and men, we conducted cross-validation with a Cancer Intervention and Surveillance Modeling Network (CISNET) model. We then incorporated smoking relapse and calibrated cessation rates to reflect the difference between a transient quit attempt and sustained abstinence. We performed external validation with the National Health Interview Survey (NHIS) and the linked National Death Index. Comparisons were based on root-mean-square error (RMSE).

Results: In cross-validation, STOP-generated projections of current/former/never smoking prevalence fit CISNET-projected data well (coefficient of variation [CV]-RMSE $\leq 15\%$). After incorporating smoking relapse, multiplying the CISNET-reported cessation rates for women/men by 7.75/7.25, to reflect the ratio of quit attempts to sustained abstinence, resulted in the best approximation to CISNET-reported smoking prevalence (CV-RMSE 2%/3%). In external validation using these new multipliers, STOP-generated cumulative mortality curves for 20-year-old current smokers and never smokers each had CV-RMSE $\leq 1\%$ compared to NHIS. In simulating those surveyed by NHIS in 1997, the STOP-projected

1
2
3 prevalence of current/former/never smokers annually (1998-2009) was similar to that reported by NHIS
4
5 (CV-RMSE 12%).
6
7
8
9

10 Conclusions: The STOP model, with relapse included, performed well when validated to US smoking
11 prevalence and mortality. STOP provides a flexible framework for policy-relevant analysis of tobacco and
12 nicotine product use.
13
14
15

16
17
18
19 Keywords: tobacco, nicotine, model, validation, calibration, relapse
20
21
22

23 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 24
25 • The STOP microsimulation model and our calibration and validation methods capture monthly
26 individual-level tobacco use behaviors and outcomes, including relapse, a key factor in nicotine
27 addiction.
28
29
- 30
31 • We validated STOP model results with those of another model and, in a partially dependent manner,
32 with empirical data.
33
34
- 35
36 • We validated with multiple outcomes, including smoking prevalence and mortality.
37
38
- 39
40 • This analysis did not account for some aspects of heterogeneity in tobacco use behaviors.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

In the US, tobacco smoking reduces life expectancy by over a decade and accounts for over \$200 billion in healthcare costs annually, approximately 9% of all healthcare costs in the country.[1,2] Though the prevalence of cigarette smoking among adults has decreased in the US, from 42% in 1965 to 14% in 2018, the decline has not been seen in all segments of society.[3,4] Meanwhile, tobacco treatment interventions, including behavioral therapy and pharmacotherapy, remain underutilized.[5] Novel tobacco and nicotine products raise many new clinical and policy questions.[6,7] Trial- and cohort-based data to fully inform these questions will not be available for many years. In the meantime, a timely way to address them is via modeling.

Simulation models provide a critical complement to more traditional research approaches.[8–14] Indeed, the Food and Drug Administration and the National Academies of Sciences, Engineering, and Medicine recently called for modeling studies to project the long-term effects, including both potential harms and benefits, of novel tobacco and nicotine products and regulatory policies to address them.[15,16] While multiple model-based studies of tobacco and nicotine products have been published,[17–25] most report aggregate trends, are focused at the population rather than individual level, and do not explicitly account for smoking relapse, a key component of the natural history and resource utilization of smoking cessation attempts. A current challenge of projecting longer-term clinical and economic outcomes of short-term tobacco cessation studies lies in capturing the many smoking quit attempts and relapses.[26,27] A new model that intentionally examines relapse would extend trial results by projecting outcomes beyond the time horizon of trials, when many relapses occur. Our objective was to develop, calibrate, and validate a novel, individual-level microsimulation model that directly addresses the mechanics of smoking initiation, cessation, and relapse, and the associated clinical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

outcomes. The intended applications of the model include projecting the downstream impact of clinical and public health policy decisions and informing the design of tobacco treatment trials.

For peer review only

METHODS

Analytic overview

We developed a microsimulation model of tobacco- and nicotine-related behaviors, clinical outcomes, and treatments: the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model. In this analysis, we focused on cigarette smoking among US women and men to demonstrate that the STOP model, in simulating individuals' month-by-month smoking behaviors, can match historical smoking prevalence and mortality data. Our methods included: 1) performing internal validation to ensure the accuracy of the mathematical calculations; 2) conducting cross-validation with another model; 3) incorporating smoking relapse and then calibrating smoking cessation probabilities to reflect the difference between a quit attempt and sustained abstinence; and 4) using our new relapse parameters, performing external validation to compare model outputs for mortality and for prevalence of current, former, and never smokers over time to empirical data from the National Health Interview Survey (NHIS) (table 1).

Table 1. Characteristics of cross-validation and external validation analyses for a new microsimulation model of smoking behaviors and outcomes.

Analysis	STOP-generated output of interest	Comparator	Measure of goodness of fit
Cross-validation ^a	1950 birth cohort prevalence of never, current, and former smokers, ages 0-70 years, by sex	CISNET-modeled 1950 birth cohort prevalence of never, current, and former smokers, ages 0-70 years, by sex	RMSE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Mortality rates of 1997-2009

External validation: mortality	Cumulative mortality by age, sex, and smoking status	NHIS respondents by age, sex, and smoking status, and cumulative mortality	MAPE and RMSE
External validation: smoking prevalence	Prevalence of never, current, and former smokers, annually, 1998-2009	NHIS never, current, and former smoking prevalence, annually, 1998-2009	RMSE

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy model. CISNET: Cancer Intervention and Surveillance Monitoring Network. NHIS: National Health Interview Survey. RMSE: root-mean-square error. MAPE: mean absolute percentage error. ^aThe initial cross-validation did not include smoking relapse. In the subsequent calibration step, we incorporated smoking relapse and calibrated cessation to achieve a good fit to the CISNET-modeled 1950 birth cohort prevalence of never, current, and former smokers.

Because there is no consensus criterion by which to compare model-generated results to surveillance data, expert guidance suggests choosing a criterion appropriate for the model structure and data sources.[28] Similar to methods used in validating other models, we chose root-mean-square error (RMSE, for cumulative risks and time-varying prevalence estimates) and mean absolute percentage error (MAPE, for mortality rates) to evaluate the goodness-of-fit between STOP model results and data sources.[28–34] We applied the coefficient of variation of RMSE (CV-RMSE) as a relative measure of error.

Smoking definitions

Similar to NHIS and the Cancer Intervention and Surveillance Modeling Network (CISNET, which used NHIS data), we defined Never Smokers as those who had smoked <100 cigarettes in their lifetime.[35–37] Among others (ever smokers), NHIS defined current smokers as those who reported currently smoking every day or some days. NHIS considered ever smokers who reported no smoking at the time of interview to be former smokers, regardless of the duration of abstinence. CISNET considered former smokers to be those who had quit smoking at least two years prior to interview; those with a shorter period of abstinence were still considered current smokers.

To better distinguish relapse and mortality risks among those with short-term or long-term abstinence, the STOP model includes three states for those who have ever smoked: 1) Current Smoker; 2) Recent Quitter (short-term abstinence); 3) Former Smoker (long-term abstinence) (figure 1). This enables a differentiation between: 1) transient quit attempts: transition from the Current Smoker state to the Recent Quitter state, with a relatively high rate of early relapse back to the Current Smoker state; and 2) sustained abstinence: transition from the Recent Quitter state to the Former Smoker state, with a lower rate of later relapse back to the Current Smoker state.

STOP model structure

STOP is an individual-level Monte Carlo microsimulation.[38,39] An individual enters the model with age and smoking status defined by random realizations from specified probability distributions. STOP follows a state-transition framework: individuals transition monthly through various cigarette smoking states (figure 1). Transitions between these states depend on age- and sex-stratified monthly smoking initiation and cessation probabilities. Ex-smokers have monthly relapse probabilities (figure 1). Monthly mortality probabilities depend on age, sex, and smoking status. Those who quit smoking retain the all-

1
2
3 cause mortality probabilities of current smokers until maintaining abstinence for a defined period of
4
5 time, after which the mortality probabilities decline.[1,8,40]
6
7
8
9

10 Individuals are simulated in series: for each simulated person, the model tracks smoking behavioral
11
12 events (smoking initiation, quit attempt, relapse) and the duration spent in each smoking state. Upon an
13
14 individual's death, the next simulated person enters the model. Once a cohort large enough to attain
15
16 stable estimates has been simulated, summary statistics are calculated, including mean number of quit
17
18 attempts, life expectancy, and the monthly prevalence of never, current, and former smokers. For the
19
20 purpose of model output displays, those in the Recent Quitter state are considered "former smokers."
21
22
23 We use a constant simulated population size of one million to obtain stable estimates of these
24
25 "average" outcomes of interest.
26
27
28
29

30 **Internal validation**

31
32 We conducted internal model validation by comparing model outputs to expected results and by
33
34 conducting sensitivity analysis.
35
36
37
38

39 **Cross-validation**

40 *Overview and outcome comparisons*

41
42 We conducted cross-validation by simulating the US population born in 1950, following them monthly
43
44 until 2020, and then comparing STOP results to those from CISNET modeling studies (table 1 and
45
46 supplementary text).[28] We selected the 1950 birth cohort because smoking prevalence in the US
47
48 peaked in the 1960s, which was the smoking initiation period (adolescence) for these individuals, and
49
50 data collection frequency increased concurrently. We compared STOP-generated results to CISNET-
51
52
53
54
55
56
57
58
59
60

1
2
3 reported results for the prevalence of female and male current, former, and never smokers over
4
5 time.[40]
6
7
8
9

10 We used CV-RMSE to assess the goodness-of-fit of the six sets of prevalence curves.[29,32] First, RMSE
11
12 was calculated as the square root of the average of the squared difference between STOP-projected
13
14 prevalence and CISNET-projected prevalence at each year of age. Then, we calculated CV-RMSE by
15
16 dividing RMSE by mean modeled prevalence, representing the relative error.
17
18
19
20

21 *CISNET Model*

22
23 CISNET is a collaboration of National Cancer Institute-supported investigators modeling the impact of
24
25 interventions on population incidence and mortality of various types of cancer, including lung cancer.
26
27 The Yale CISNET-Lung models, for subsequent analyses of cancer care interventions, used data from
28
29 NHIS to generate detailed smoking initiation and cessation rates, stratified by birth year, age, and sex,
30
31 and mortality rates, stratified by birth year, age, sex, and smoking status.[37,41]
32
33
34
35
36

37 *Input parameters for initial cross-validation*

38
39 For the initial cross-validation exercise, we used data from CISNET modeling studies, which were derived
40
41 from NHIS through 2009 and were stratified by birth cohort (table 2).[37,41] Specifically, we used
42
43 CISNET age- and sex-stratified smoking initiation and cessation rates and smoking-stratified mortality
44
45 rates among US women and men born in 1950, converting them to monthly probabilities. The CISNET
46
47 smoking cessation rates reflected a direct transition from current smoker to former smoker after at least
48
49 two years of sustained abstinence.[41] This initial exercise used the same input parameters as CISNET
50
51 and did not include smoking relapse.
52
53
54
55
56
57
58
59
60

Table 2. STOP model input parameters applied in each validation exercise.

Input parameter	Cross-validation	External validation of mortality	External validation of smoking prevalence
Input parameters from CISNET (for cross-validation), NHIS 1997-2009 (for external validation of mortality), or NHIS 1997 (for external validation of smoking prevalence)			
Baseline cohort characteristics			
Women/Men, % ^a	---	52/48	52/48
Initial age, mean, years (SD)	0 (followed a birth cohort)	39.7 (21.4)	39.1 (20.7)
Minimum/maximum age, years	---	18/84	18/84
Initial prevalence of			
never/current/former smokers ^b , %	100/0/0	56/22/22	52/25/23
Years since cessation among former smokers, mean (SD)	---	15.6 (12.7)	14.4 (11.9)
Smoking behavior events ^c			
Monthly smoking initiation probability, by age and sex	0-0.0093	0-0.0063	0-0.0063
Monthly smoking cessation probability, by age and sex	0-0.015	0-0.035	0-0.035
Mortality			

1	Monthly mortality probability ^d ,			
2	by age and sex, x 10 ⁻⁴			
3				
4				
5				
6				
7	Never smokers	0-12.8	0.4-95.2	0.4-95.2
8				
9	Current smokers	0-34.6	0.4-136.1	0.4-136.1
10				
11				
12		Multiplier applied		
13	Former smokers		0-111.5	0-111.5
14		(see last row)		
15				

Input parameters derived from smoking studies or from authors' calibration

16	Monthly relapse probability ^e			
17	(t = months since cessation)	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$
18				
19	Cessation rate multiplier			
20	(calibrated), women/men	7.75/7.25	7.75/7.25	7.5/7
21				
22	Initiation rate multiplier			
23	(calibrated), women/men	---	---	0.9/1.0
24				
25	Former smoker mortality			
26	multiplier, applied to never			
27	smoker mortality, by sex	1.0-2.2	---	---
28	and age at quit ^f			

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. CISNET: Cancer Intervention and Surveillance Modeling Network. NHIS: National Health Interview Survey. SD: standard deviation. The numbers show model input parameters applied in cross-validation (left column), external validation of mortality (center column), and external validation of smoking prevalence (right column).

^aIn cross-validation, we simulated cohorts of either all women or all men from birth. Thus, no distributions of initial age are displayed.

^bPrevalence of each smoking status displayed here is the mean over all strata, but in the model these were stratified by 5-year age group and sex from ages 18 to 84.

^cAdditional details about smoking behavior transitions are in supplementary table 1.

^dAdditional details about mortality data are in supplementary table 2.

^eThis is based on relapse probabilities reported in smoking cessation intervention trials, focusing on placebo arms.[42–45]

^fFor the 1950 birth cohort, some CISNET-derived former smoker mortality rates are lower than CISNET-derived never smoker mortality rates – a counterintuitive relationship otherwise unexplained. We therefore adapted former smoker mortality multipliers for the cross-validation from Thun et al.[40]

Incorporating smoking relapse and calibrating cessation probabilities

The STOP model specifically includes smoking relapse, critical to projecting both short-term and long-term impacts of smoking cessation interventions and novel tobacco and nicotine products.

Following the initial cross-validation of the STOP model (without relapse), we added smoking relapse probabilities and then recalibrated the model by adjusting the previously-applied smoking cessation probabilities. First, we modeled relapse as an exponential decay function of time since quit, such that the highest risk of relapse was in the first month after a quit attempt. The coefficient and time constant

1
2
3 are based on relapse probabilities in smoking cessation trials (table 2).[42–45] Second, we calibrated the
4
5 previously-applied cessation probabilities (derived from CISNET cessation data) by a multiplier to reflect:
6
7 1) a quit attempt rather than sustained abstinence; and 2) the higher likelihood of making a quit attempt
8
9 rather than attaining sustained abstinence in a given month. This multiplier represents the average
10
11 number of quit attempts, lasting at least one month, prior to attaining sustained abstinence. We
12
13 compared our multipliers to published data on the average number of quit attempts required to attain
14
15 sustained abstinence.[27] Our overall aim for this calibration step was to identify a STOP-generated
16
17 current smoker prevalence curve with an RMSE <0.01 compared to the CISNET model-generated current
18
19 smoker prevalence curve, similar to previously described methods.[32]
20
21
22
23
24

25 **External validation**

26 *Overview and outcome comparisons*

27
28 For external validation, we compared STOP model results to NHIS data.[28,36] We accounted for
29
30 smoking initiation, smoking cessation, and mortality. Because NHIS data do not explicitly report relapse,
31
32 we incorporated smoking relapse and the best-fitting cessation multipliers found in the cross-validation
33
34 calibration step. We compared two outcomes: mortality and smoking prevalence (table 1 and
35
36 supplementary text).
37
38
39
40
41
42

43 First, to project and validate mortality outcomes, we simulated the population surveyed by NHIS from
44
45 1997 through 2009 (supplementary text). To compare STOP-generated mortality rates to those derived
46
47 from NHIS – stratified by age, sex, and smoking status – we used MAPE, the mean absolute value of the
48
49 percent difference between STOP and NHIS values. We also produced curves of cumulative mortality
50
51 from STOP-generated results and from NHIS data, stratified by sex and by current/never smoking status.
52
53 These curves reflect 20-year-old current smokers who continue to smoke until death or 20-year-old
54
55
56
57
58
59
60

1
2
3 never smokers who never start smoking. We compared the four sets of cumulative mortality curves by
4
5 RMSE and CV-RMSE (STOP versus NHIS) from age 20 years until age 84 years (goal RMSE <0.01). We did
6
7 not generate mortality curves for 20-year-old former smokers because mortality risks for those who
8
9 stop smoking prior to age 20 are similar to those of never smokers.[1] Also, mortality risks depend on
10
11 age at cessation, and at older ages this heterogeneous group would include people who quit smoking at
12
13 a variety of ages.[1,40]
14
15

16
17
18
19 Second, with those surveyed by NHIS in 1997 as the input cohort, we used the STOP model to project
20
21 the prevalence of current, former, and never smokers each year from 1998 to 2009. In a two-way
22
23 sensitivity analysis, we re-calibrated cessation multipliers and initiation multipliers with the goal of
24
25 identifying multipliers that would minimize the CV-RMSE of STOP-reported current smoker prevalence
26
27 compared to NHIS current smoker prevalence. The initiation multipliers were applied to smoking
28
29 initiation rates for never smokers. We then compared the cessation multipliers from this step with those
30
31 from the cross-validation calibration step.
32
33

34 35 36 37 *Input parameters*

38
39 Initial distributions of age, sex, and smoking status for the population simulated in the external
40
41 validation exercises came from two sources: aggregated 1997-2009 NHIS data for the mortality external
42
43 validation, and 1997 NHIS data for the smoking prevalence external validation (table 2 and
44
45 supplementary figure 1). We obtained NHIS data in aggregate for years 1997-2009 from the Integrated
46
47 Public Use Microdata Series.[35] We used NHIS data through 2009 because those were the data used in
48
49 the CISNET studies, which were our comparator in cross-validation exercises.[37,41] These data
50
51 provided initial distributions of smoking status and years of abstinence for former smokers (to inform
52
53 relapse risks). From these 1997-2009 NHIS data, we derived age- and sex-specific smoking initiation and
54
55
56
57

1
2
3 cessation rates using self-reported age at initiation and age at cessation variables (supplementary table
4
5 1). As in our cross-validation exercises, we converted the cessation rates to quit attempt rates by
6
7 incorporating relapse rates and cessation multipliers.
8
9

10
11
12 The NHIS data included linked National Death Index (NDI) mortality outcomes through 2011 for
13
14 respondents for whom mortality data were available. We calculated mortality rates by age, sex, and
15
16 smoking status of the same NHIS respondents (supplementary table 1).
17
18

19 20 21 **Patient and public involvement**

22
23 We did not involve patients or the public in our work.
24
25

26 27 28 **Ethics statement**

29
30 This study was approved by the Partners Human Research Committee (2019P001772).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Cross-validation

Initial cross-validation, without relapse

The STOP-projected prevalence of current, former, and never smokers over time fit CISNET-projected data well for the 1950 birth cohort in the US (figure 2, blue line vs. red dotted line, RMSE <0.03, CV-RMSE 15%/7% for women/men). The STOP-estimated prevalence of current smokers at age 25 years, approaching peak prevalence for the 1950 birth cohort, was 40% for women and 54% for men, compared to CISNET estimates of 38% and 52%.

Incorporating smoking relapse and calibrating cessation probabilities

After incorporating smoking relapse, the prevalence of current smokers far exceeded that reported by the CISNET model, as expected since many of those who would have become former smokers reverted to being current smokers (figure 2, pink dashed lines). We then aimed to reflect all quit attempts rather than only transitions to sustained abstinence. In rough calibrations, we found that the optimal multiplier would be between 5 and 10 when applied to cessation rates from the previous step. In finer calibrations, we varied the multiplier across the range of 5 to 10 in increments of 0.25. We found that multiplying the CISNET-reported cessation rates by 7.75 for women and by 7.25 for men best approximated the CISNET-projected prevalence of current smokers, with RMSE 0.004/0.008 and CV-RMSE 2%/3% for women/men (figure 2, black lines).

External validation

Mortality

In simulating the 1997-2009 NHIS population along with smoking relapse, we found that the age-, sex-, and smoking-stratified mortality rates generated by the STOP model were a good fit to those derived

1
2
3 from NHIS (MAPE 7%, examples in supplementary table 2). Cumulative mortality curves for 20 year-old
4
5 female and male current smokers and never smokers were similar between STOP projections and NHIS-
6
7 derived data, with RMSE <0.01 and CV-RMSE \leq 1% (figure 3). For 20-year-olds who continued to smoke
8
9 until death, the STOP model predicted median life expectancy (counting years from birth) of 77.5 years
10
11 for women and 72.5 years for men.
12
13

14 15 16 *Smoking prevalence*

17
18 Using those surveyed by NHIS in 1997 as the input cohort, the STOP-projected prevalence of current,
19
20 former, and never smokers each year from 1998 to 2009 was similar to that reported by NHIS, with
21
22 overall RMSE 0.04 and CV-RMSE 12% for both women and men (ages 30-84 years combined;
23
24 supplementary figure 2 shows results specifically for ages 40-44 years). Compared to NHIS, the STOP
25
26 model slightly underpredicted never smoker prevalence and slightly overpredicted former smoker
27
28 prevalence in later years. In the two-way sensitivity analysis, we found that cessation multipliers of
29
30 7.5/7.0 for women/men and initiation multipliers of 0.9/1.0 provided the best overall fit (lowest RMSE)
31
32 of STOP-projected current smoker prevalence compared to that reported by NHIS (supplementary figure
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 3).

DISCUSSION

We developed, calibrated, and validated STOP, a novel microsimulation model of individual-level tobacco use behaviors and outcomes. Our initial model input parameters included smoking initiation and cessation and smoking-stratified mortality, and we demonstrated cross-validity compared to the CISNET model. After incorporating relapse, we calibrated smoking cessation probabilities to reflect quit attempts rather than sustained abstinence. We then validated STOP model output with: 1) smoking prevalence over time reported by the CISNET model for US women and men born in 1950; 2) age-, sex-, and smoking-stratified mortality rates and cumulative mortality reported by the NHIS-NDI linked database for the years 1997-2009; and 3) prevalence of current, former, and never smokers by sex from 1998 to 2009 reported by NHIS, using 1997 NHIS-reported population characteristics as inputs.

Most existing tobacco models simulate at the population level or lack the capacity to consider smoking initiation and (non-sustained) quit attempts throughout a lifetime.[18,23–25,37,46,47] The individual-level details of STOP can be employed to simulate and compare behaviors and interventions. While this calibration and validation analysis focused on cigarette smoking because of the availability of historical data for comparisons, we intend to broaden the use of STOP to include electronic cigarettes (e-cigs). Longitudinal cohort studies and clinical trials are examining the effects of e-cig use on tobacco smoking behaviors and clinical outcomes over long time horizons, but data are needed now to inform guidelines and policy around these novel products.[15,44,48,49] Results from multiple distinct, validated models can help motivate policy decisions, and consistency of policy recommendations across unique, independent models reinforces confidence in their recommendations.[50–54]

A novel aspect of the STOP model is the incorporation of smoking relapse on a monthly basis, reflecting the understanding of nicotine addiction as a chronic relapsing condition with rapid cycles between use

1
2
3 and cessation.[26,45,55–58] This key feature enables an important distinction between a quit attempt
4 and sustained abstinence. This distinction is missing from most tobacco models and indeed from many
5 epidemiologic studies of smoking and smoking cessation, which consider the transition from “current”
6 to “former” smoker to be an abrupt one that results in sustained abstinence. Incorporating relapse
7 required calibrating cessation rates by applying multipliers. The cessation multipliers that provided the
8 best fits to empirical data are in line with published data regarding the number of quit attempts
9 required before sustained abstinence is achieved.[27,55,59] The slightly higher multiplier needed for
10 women compared to men is consistent with NHIS data showing that among ever smokers (current
11 smokers plus former smokers) aged 60 years and above, a greater proportion of women compared to
12 men are former smokers.[35] Calibration of cessation rates may compensate for other inaccuracies in
13 model inputs or structure, though the pre-calibration (without relapse) STOP-generated results fit well
14 with those of CISNET.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Many trials of smoking cessation interventions follow patients for a few months or up to one year, but
33 they do not report subsequent relapse. By including relapse, the STOP model can combine data from
34 short-term trials of smoking cessation interventions with data from natural history studies of smoking
35 and smoking cessation to project longer-term outcomes including sustained abstinence. The flexibility to
36 integrate data from a variety of sources is a strength of modeling analyses.
37
38
39
40
41
42
43
44
45

46 Going forward, we plan to use the STOP model to study contemporary rather than historical populations
47 and to predict future tobacco use, while utilizing deterministic and probabilistic sensitivity analyses to
48 account for uncertainty in future behavioral transition probabilities and mortality probabilities.[60] As
49 no empirical data exist with which to validate model output of future tobacco use, we validated STOP
50 model output against historical populations. Most US historical data on smoking prevalence and
51
52
53
54
55
56
57
58
59
60

1
2
3 smoking-associated mortality are based at least in part on NHIS, the oldest ongoing survey of smoking
4 prevalence in the US.[1,61–63] We compared STOP model output to CISNET model output, to NHIS
5 itself, and to results from a study by Jha et al.,[1] all of which used NHIS data. We demonstrated cross-
6 validity of STOP compared to CISNET model results when using CISNET input parameters and then added
7 relapse probabilities and cessation multipliers. We demonstrated external validity, in a partially
8 dependent manner, of STOP compared to NHIS data when using some NHIS-derived input parameters
9 plus the external relapse probabilities and cessation multipliers from our cross-validation. Though
10 independent external validation sources are ideal, dependent sources can still be useful, especially in
11 this scenario where most of the available US historical smoking prevalence, behavior, and mortality data
12 are derived from NHIS.[28] Of note, in a two-way sensitivity analysis in which we simultaneously varied
13 the smoking initiation and cessation multipliers to achieve a close fit to NHIS smoking prevalence data,
14 the optimal cessation multipliers were very similar to those we found in our cross-validation calibration
15 step, demonstrating the robustness of these multipliers across different sets of assumptions.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 In an external validation exercise, the STOP model projection for never smoker prevalence from 1998 to
36 2009 was slightly lower than that reported by NHIS, and the STOP model projection for former smoker
37 prevalence was slightly higher than NHIS data. In NHIS, former smokers were self-defined but on
38 average had been abstinent for over a decade. NHIS considered those who smoked “some days” to be
39 current smokers, though some of them may have been in the midst of a short-duration quit attempt.
40 STOP model output formally labels these people, who may be in the Recent Quitter state, former
41 smokers but assigns them the mortality risks of current smokers (until a defined period of abstinence).
42 STOP reflects monthly quitting and relapsing behaviors whereas NHIS is an annual cross-sectional
43 survey. Thus, one would expect the STOP model to report a higher prevalence of former smokers than
44 NHIS, as seen in our results. Immigration could also account for some of the difference between NHIS
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 data and STOP model-generated results: immigrants were surveyed in NHIS but our model analysis does
4 not account for them. Smoking prevalence differs between the immigrant and non-immigrant
5 populations.[64,65] On the other hand, STOP model-generated life expectancies were similar to the
6 median life expectancies for 30-year-old smokers reported by Jha et al. (also derived from NHIS data): 77
7 years for women and 72 years for men.[1]
8
9
10
11
12
13
14
15

16 The STOP model has features, and will have applications, not described in this analysis. We developed
17 the model to incorporate resource utilization. The STOP model can capture the healthcare costs
18 associated with being a current, former, or never smoker, as well as the costs of tobacco cessation
19 interventions. By incorporating the chronic relapsing nature of nicotine addiction, the STOP model can
20 account for the resources required for recurrent cessation interventions (e.g., restarting the same or a
21 different intervention after smoking relapse), an important consideration in cost-effectiveness and
22 policy analyses. Ultimately, we will use the STOP model to evaluate behavioral and clinical outcomes,
23 costs of care, and cost-effectiveness of tobacco cessation interventions, programs, and policies. An
24 overarching goal is to provide information that can inform decision makers – including clinicians, public
25 health officials, and policymakers – on cost-effective interventions that reduce the clinical and economic
26 burden of tobacco use. The model can eventually assess the impact of different financing options for
27 tobacco cessation interventions – for example, annual versus lifetime insurance coverage limits. The
28 STOP model’s flexibility will allow for analyses beyond US populations, including settings where
29 smoking-related behaviors and clinical outcomes may be different from those in the US.[66]
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 The STOP model has limitations. Its projections are limited by assumptions and the specificity of
51 available data – for example, age, sex, and birth year stratifications of smoking behavioral transitions.
52 While we have aimed to calibrate and validate the model with the best available historical data, any use
53
54
55
56
57
58
59
60

1
2
3 of the model to project future outcomes should be approached with prudence. Calibration on historical
4 data is no panacea because of concerns of calibration drift, and relapse rates could change over time
5 due to changes in population-level nicotine dependence.[67] Nonetheless, input parameter values can
6 be varied in sensitivity analysis. STOP does not include dynamics such as the effects of one person's
7 smoking on another person's smoking behaviors. Smoking is associated with other factors not directly
8 captured by STOP, including race, socioeconomic status, mental illness, and other substance use, but
9 different populations can be separately simulated in the model with input parameters specific to that
10 population. There is heterogeneity in smoking behaviors, including cigarettes consumed per day and
11 daily versus nondaily smoking. STOP enables stratification by intensity of smoking, which can be used to
12 represent amount or frequency of smoking.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 In conclusion, STOP is a novel, individual-level microsimulation model that captures tobacco-related
29 behaviors – importantly including relapse – and outcomes with a goal of informing decision making
30 around tobacco cessation interventions and tobacco policy. We have demonstrated that the model is
31 well-calibrated and validated to another model and to historical cohorts. We plan to use the model for
32 policy-relevant analysis of contemporary patient-level and population-level care while reflecting real-life
33 tobacco use and cessation behaviors.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHOR CONTRIBUTIONS

Specific contributions are as follows:

KPR – study conception, study design, data analysis, data interpretation

AJB – study design, data analysis, data interpretation

DEL – study design, data interpretation

PT – data analysis, data interpretation

EPH – study design, data interpretation

TH – study conception, study design, data analysis

BO – study design

LY – data analysis, data interpretation

FMS – study design, data analysis, data interpretation

ADP – study design, data interpretation

KAF – study design, data interpretation

MCW – study design, data interpretation

NAR – study conception, study design, data interpretation

RPW – study conception, study design, data interpretation

KPR drafted the first version of the manuscript. All authors critically reviewed the manuscript for important intellectual content and approved the final submitted version.

COMPETING INTERESTS

NAR receives royalties from UpToDate, Inc., is a consultant for Achieve Life Sciences, and has been an unpaid consultant for Pfizer. All other authors report no competing interests.

SOURCES OF FUNDING

This work was supported by awards from the National Institute on Drug Abuse (K01 DA042687) and the National Heart, Lung, and Blood Institute (K01 HL123349) of the National Institutes of Health, and the Steve and Deborah Gorlin MGH Research Scholars Award. The funding sources had no role in the design, analysis, or interpretation of the study, the writing of the manuscript, or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Massachusetts General Hospital.

DATA STATEMENT

Data used to parameterize the model are publicly available at <https://resources.cisnet.cancer.gov/projects> and at <https://nhis.ipums.org/nhis>.

REFERENCES

- 1 Jha P, Ramasundarahettige C, Landsman V, *et al*. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;**368**:341–50. doi:10.1056/NEJMsa1211128
- 2 Xu X, Bishop EE, Kennedy SM, *et al*. Annual healthcare spending attributable to cigarette smoking: an update. *Am J Prev Med* 2015;**48**:326–33. doi:10.1016/j.amepre.2014.10.012
- 3 US Department of Health and Human Services. *The health consequences of smoking-50 years of progress: a report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014. <https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/index.html>
- 4 Creamer MR, Wang TW, Babb S, *et al*. Tobacco product use and cessation indicators among adults - United States, 2018. *MMWR Morb Mortal Wkly Rep* 2019;**68**:1013–9. doi:10.15585/mmwr.mm6845a2
- 5 Patel KK, Jones PG, Ellerbeck EF, *et al*. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry. *J Am Heart Assoc* 2018;**7**:e010076. doi:10.1161/JAHA.118.010076
- 6 Office of the Commissioner, US Food and Drug Administration. FDA finalizes guidance for premarket tobacco product applications for electronic nicotine delivery systems as part of commitment to continuing a strong oversight of e-cigarettes. 11 Jun 2019. <http://www.fda.gov/news-events/press-announcements/fda-finalizes-guidance-premarket-tobacco-product-applications-electronic-nicotine-delivery-systems> (accessed 9 Jan 2020).
- 7 Office of the Commissioner, US Food and Drug Administration. FDA permits sale of IQOS Tobacco Heating System through premarket tobacco product application pathway. 30 Apr 2019. <http://www.fda.gov/news-events/press-announcements/fda-permits-sale-iqos-tobacco-heating-system-through-premarket-tobacco-product-application-pathway> (accessed 9 Jan 2020).
- 8 Reddy KP, Parker RA, Losina E, *et al*. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. *J Infect Dis* 2016;**214**:1672–81. doi:10.1093/infdis/jiw430
- 9 Reddy KP, Kong CY, Hyle EP, *et al*. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. *JAMA Intern Med* 2017;**177**:1613–21. doi:10.1001/jamainternmed.2017.4349
- 10 Apelberg BJ, Feirman SP, Salazar E, *et al*. Potential public health effects of reducing nicotine levels in cigarettes in the United States. *N Engl J Med* 2018;**378**:1725–33. doi:10.1056/NEJMsr1714617
- 11 Walensky RP, Ross EL, Kumarasamy N, *et al*. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med* 2013;**369**:1715–25. doi:10.1056/NEJMsa1214720

- 1
2
3 12 Reddy KP, Gupta-Wright A, Fielding KL, *et al.* Cost-effectiveness of urine-based tuberculosis
4 screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. *Lancet Glob*
5 *Health* 2019;**7**:e200–8. doi:10.1016/S2214-109X(18)30436-4
6
7 13 Weinstein MC, O'Brien B, Hornberger J, *et al.* Principles of good practice for decision analytic
8 modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--
9 Modeling Studies. *Value Health* 2003;**6**:9–17. doi:10.1046/j.1524-4733.2003.00234.x
10
11 14 Sanders GD, Neumann PJ, Basu A, *et al.* Recommendations for conduct, methodological practices,
12 and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and
13 Medicine. *JAMA* 2016;**316**:1093–103. doi:10.1001/jama.2016.12195
14
15 15 National Academies of Sciences, Engineering, and Medicine. *Public Health Consequences of E-*
16 *Cigarettes*. Washington, DC: : The National Academies Press 2018. doi:10.17226/24952
17
18 16 Office of Disease Prevention, National Institutes of Health. Tobacco regulatory research priorities.
19 <https://prevention.nih.gov/tobacco-regulatory-research/tobacco-regulatory-research-priorities>
20 (accessed 9 Jan 2020).
21
22 17 Levy DT, Cummings KM, Villanti AC, *et al.* A framework for evaluating the public health impact of e-
23 cigarettes and other vaporized nicotine products. *Addiction* 2017;**112**:8–17. doi:10.1111/add.13394
24
25 18 Levy DT, Yuan Z, Li Y, *et al.* A modeling approach to gauging the effects of nicotine vaping product
26 use on cessation from cigarettes: what do we know, what do we need to know? *Addiction* 2019;**114**
27 **Suppl 1**:86–96. doi:10.1111/add.14530
28
29 19 Warner KE, Mendez D. E-cigarettes: comparing the possible risks of increasing smoking initiation
30 with the potential benefits of increasing smoking cessation. *Nicotine Tob Res* 2019;**21**:41–7.
31 doi:10.1093/ntr/nty062
32
33 20 Cherng ST, Tam J, Christine P, *et al.* Modeling the effects of e-cigarettes on smoking behavior:
34 implications for future adult smoking prevalence. *Epidemiology* 2016;**27**:819–26.
35 doi:10.1097/EDE.0000000000000497
36
37 21 Kalkhoran S, Glantz SA. Modeling the health effects of expanding e-cigarette sales in the United
38 States and United Kingdom: a Monte Carlo analysis. *JAMA Intern Med* 2015;**175**:1671–80.
39 doi:10.1001/jamainternmed.2015.4209
40
41 22 Vugrin ED, Rostron BL, Verzi SJ, *et al.* Modeling the potential effects of new tobacco products and
42 policies: a dynamic population model for multiple product use and harm. *PLoS One*
43 2015;**10**:e0121008. doi:10.1371/journal.pone.0121008
44
45 23 Levy DT, Borland R, Lindblom EN, *et al.* Potential deaths averted in USA by replacing cigarettes with
46 e-cigarettes. *Tob Control* 2018;**27**:18–25. doi:10.1136/tobaccocontrol-2017-053759
47
48 24 Soneji SS, Sung H-Y, Primack BA, *et al.* Quantifying population-level health benefits and harms of e-
49 cigarette use in the United States. *PLoS One* 2018;**13**:e0193328. doi:10.1371/journal.pone.0193328
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 25 Levy DT, Borland R, Villanti AC, *et al.* The application of a decision-theoretic model to estimate the
4 public health impact of vaporized nicotine product initiation in the United States. *Nicotine Tob Res*
5 2017;**19**:149–59. doi:10.1093/ntr/ntw158
6
7 26 Hughes JR, Solomon LJ, Naud S, *et al.* Natural history of attempts to stop smoking. *Nicotine Tob Res*
8 2014;**16**:1190–8. doi:10.1093/ntr/ntu052
9
10 27 Chaiton M, Diemert L, Cohen JE, *et al.* Estimating the number of quit attempts it takes to quit
11 smoking successfully in a longitudinal cohort of smokers. *BMJ Open* 2016;**6**:e011045.
12 doi:10.1136/bmjopen-2016-011045
13
14 28 Eddy DM, Hollingworth W, Caro JJ, *et al.* Model transparency and validation: a report of the ISPOR-
15 SMDM Modeling Good Research Practices Task Force-7. *Med Decis Making* 2012;**32**:733–43.
16 doi:10.1177/0272989X12454579
17
18 29 Vanni T, Karnon J, Madan J, *et al.* Calibrating models in economic evaluation: a seven-step approach.
19 *Pharmacoeconomics* 2011;**29**:35–49. doi:10.2165/11584600-000000000-00000
20
21 30 Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative measures
22 of goodness of fit, parameter search strategies and convergence criteria. *Pharmacoeconomics*
23 2011;**29**:51–62. doi:10.2165/11584610-000000000-00000
24
25 31 Cevik M, Ergun MA, Stout NK, *et al.* Using active learning for speeding up calibration in simulation
26 models. *Med Decis Making* 2016;**36**:581–93. doi:10.1177/0272989X15611359
27
28 32 Ciaranello AL, Morris BL, Walensky RP, *et al.* Validation and calibration of a computer simulation
29 model of pediatric HIV infection. *PLoS One* 2013;**8**:e83389. doi:10.1371/journal.pone.0083389
30
31 33 Rydzak CE, Cotich KL, Sax PE, *et al.* Assessing the performance of a computer-based policy model of
32 HIV and AIDS. *PLoS One* 2010;**5**. doi:10.1371/journal.pone.0012647
33
34 34 Kazemian P, Wexler DJ, Fields NF, *et al.* Development and validation of PREDICT-DM: a new
35 microsimulation model to project and evaluate complications and treatments of type 2 diabetes
36 mellitus. *Diabetes Technol Ther* 2019;**21**:344–55. doi:10.1089/dia.2018.0393
37
38 35 Blewett LA, Rivera Drew JA, Griffin R, *et al.* *IPUMS Health Surveys: National Health Interview Survey,*
39 *Version 6.3 [dataset]*. Minneapolis, MN: IPUMS. <https://nhis.ipums.org> (accessed 9 Jan 2020).
40
41 36 Centers for Disease Control and Prevention. National Health Interview Survey. Adult tobacco use -
42 major changes. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_changes.htm (accessed 9 Jan
43 2020).
44
45 37 Holford TR, Meza R, Warner KE, *et al.* Tobacco control and the reduction in smoking-related
46 premature deaths in the United States, 1964-2012. *JAMA* 2014;**311**:164–71.
47 doi:10.1001/jama.2013.285112
48
49 38 Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation.
50 *Pharmacoeconomics* 2006;**24**:1043–53. doi:10.2165/00019053-200624110-00002
51
52
53
54
55
56
57
58
59
60

- 1
2
3 39 Rutter CM, Zaslavsky A, Feuer E. Dynamic microsimulation models for health outcomes: a review.
4 *Med Decis Making* 2011;**31**:10–8. doi:10.1177/0272989X10369005
5
6 40 Thun MJ, Carter BD, Feskanich D, *et al.* 50-year trends in smoking-related mortality in the United
7 States. *N Engl J Med* 2013;**368**:351–64. doi:10.1056/NEJMsa1211127
8
9 41 Holford TR, Levy DT, McKay LA, *et al.* Patterns of birth cohort-specific smoking histories, 1965-2009.
10 *Am J Prev Med* 2014;**46**:e31-37. doi:10.1016/j.amepre.2013.10.022
11
12 42 Tonstad S, Tønnesen P, Hajek P, *et al.* Effect of maintenance therapy with varenicline on smoking
13 cessation: a randomized controlled trial. *JAMA* 2006;**296**:64–71. doi:10.1001/jama.296.1.64
14
15 43 Brendryen H, Kraft P. Happy Ending: a randomized controlled trial of a digital multi-media smoking
16 cessation intervention. *Addiction* 2008;**103**:478–84. doi:10.1111/j.1360-0443.2007.02119.x
17
18 44 Bullen C, Howe C, Laugesen M, *et al.* Electronic cigarettes for smoking cessation: a randomised
19 controlled trial. *Lancet* 2013;**382**:1629–37. doi:10.1016/S0140-6736(13)61842-5
20
21 45 Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated
22 smokers. *Addiction* 2004;**99**:29–38. doi:10.1111/j.1360-0443.2004.00540.x
23
24 46 Warner KE, Mendez D. E-cigarettes: comparing the possible risks of increasing smoking initiation
25 with the potential benefits of increasing smoking cessation. *Nicotine Tob Res* 2019;**21**:41–7.
26 doi:10.1093/ntr/nty062
27
28 47 Feuer EJ, Levy DT, McCarthy WJ. Chapter 1: The impact of the reduction in tobacco smoking on U.S.
29 lung cancer mortality, 1975–2000: an introduction to the problem. *Risk Analysis* 2012;**32**:S6–13.
30 doi:10.1111/j.1539-6924.2011.01745.x
31
32 48 Hajek P, Phillips-Waller A, Przulj D, *et al.* A randomized trial of e-cigarettes versus nicotine-
33 replacement therapy. *N Engl J Med* 2019;**380**:629–37. doi:10.1056/NEJMoa1808779
34
35 49 Population Assessment of Tobacco and Health (PATH).
36 <https://pathstudyinfo.nih.gov/UI/HomeMobile.aspx> (accessed 9 Jan 2020).
37
38 50 Paltiel AD, Weinstein MC, Kimmel AD, *et al.* Expanded screening for HIV in the United States--an
39 analysis of cost-effectiveness. *N Engl J Med* 2005;**352**:586–95. doi:10.1056/NEJMsa042088
40
41 51 Sanders GD, Bayoumi AM, Sundaram V, *et al.* Cost-effectiveness of screening for HIV in the era of
42 highly active antiretroviral therapy. *N Engl J Med* 2005;**352**:570–85. doi:10.1056/NEJMsa042657
43
44 52 Dugdale CM, Ciaranello AL, Bekker L-G, *et al.* Risks and benefits of dolutegravir- and efavirenz-based
45 strategies for South African women with HIV of child-bearing potential: a modeling study. *Ann*
46 *Intern Med* 2019;**170**:614–25. doi:10.7326/M18-3358
47
48 53 Phillips AN, Venter F, Havlir D, *et al.* Risks and benefits of dolutegravir-based antiretroviral drug
49 regimens in sub-Saharan Africa: a modelling study. *Lancet HIV* 2019;**6**:e116–27. doi:10.1016/S2352-
50 3018(18)30317-5
51
52
53
54
55
56
57
58
59
60

- 1
2
3 54 Berry DA, Cronin KA, Plevritis SK, *et al.* Effect of screening and adjuvant therapy on mortality from
4 breast cancer. *N Engl J Med* 2005;**353**:1784–92. doi:10.1056/NEJMoa050518
5
- 6 55 Borland R, Partos TR, Yong H-H, *et al.* How much unsuccessful quitting activity is going on among
7 adult smokers? Data from the International Tobacco Control Four Country cohort survey. *Addiction*
8 2012;**107**:673–82. doi:10.1111/j.1360-0443.2011.03685.x
9
- 10 56 Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: findings from
11 the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2009;**104**:2088–99.
12 doi:10.1111/j.1360-0443.2009.02732.x
13
- 14 57 Herd N, Borland R. The natural history of quitting smoking: findings from the International Tobacco
15 Control (ITC) Four Country Survey. *Addiction* 2009;**104**:2075–87. doi:10.1111/j.1360-
16 0443.2009.02731.x
17
- 18 58 National Institute on Drug Abuse. The science of drug use and addiction: the basics.
19 <https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics> (accessed
20 9 Jan 2020).
21
- 22 59 Jones JM. Smoking habits stable; most would like to quit. 18 Jul 2006. Gallup.com.
23 <https://news.gallup.com/poll/23791/Smoking-Habits-Stable-Most-Would-Like-Quit.aspx> (accessed 9
24 Jan 2020).
25
- 26 60 Briggs AH, Weinstein MC, Fenwick EAL, *et al.* Model parameter estimation and uncertainty analysis:
27 a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. *Med*
28 *Decis Making* 2012;**32**:722–32. doi:10.1177/0272989X12458348
29
- 30 61 Wang TW, Asman K, Gentzke AS, *et al.* Tobacco product use among adults - United States, 2017.
31 *MMWR Morb Mortal Wkly Rep* 2018;**67**:1225–32. doi:10.15585/mmwr.mm6744a2
32
- 33 62 Babb S, Malarcher A, Schauer G, *et al.* Quitting smoking among adults - United States, 2000-2015.
34 *MMWR Morb Mortal Wkly Rep* 2017;**65**:1457–64. doi:10.15585/mmwr.mm6552a1
35
- 36 63 Garrett BE, Dube SR, Trosclair A, *et al.* Cigarette smoking - United States, 1965-2008. *MMWR Suppl*
37 2011;**60**:109–13.
38
- 39 64 Bosdriesz JR, Lichthart N, Witvliet MI, *et al.* Smoking prevalence among migrants in the US
40 compared to the US-born and the population in countries of origin. *PLoS One* 2013;**8**:e58654.
41 doi:10.1371/journal.pone.0058654
42
- 43 65 Pampel F, Khat M, Bricard D, *et al.* Smoking among immigrant groups in the United States:
44 prevalence, education gradients, and male-to-female ratios. *Nicotine Tob Res* Published Online First:
45 13 February 2019. doi:10.1093/ntr/ntz022
46
- 47 66 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195
48 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study
49 2015. *Lancet* 2017;**389**:1885–906. doi:10.1016/S0140-6736(17)30819-X
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

67 Yi Z, Mayorga ME, Hassmiller Lich K, *et al.* Changes in cigarette smoking initiation, cessation, and relapse among U.S. adults: a comparison of two longitudinal samples. *Tob Induc Dis* 2017;**15**:17. doi:10.1186/s12971-017-0121-3

For peer review only

FIGURE LEGENDS

Figure 1. Overview of tobacco use states and transitions in Simulation of Tobacco and Nicotine

Outcomes and Policy (STOP) microsimulation model.

This is a simplified, stylized depiction of smoking states and transitions – for example, dimensions such as age and sex are not represented in the figure. The ovals represent possible cigarette smoking states or the deceased state. The arrows represent monthly transitions by which an individual can switch to a different state. The “Abstinence, sustained” transition is depicted by a dashed line because there is not a monthly probability of transition – instead, the transition occurs after an individual has spent a user-defined duration (e.g., one year) in the “Recent Quitter” state. Numerical examples of the transition probabilities are in supplementary table 1.

Figure 2. Cross-validation and calibration exercise: STOP-generated results and CISNET-generated results for current smoking prevalence over time for US people born in 1950.

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy model. CISNET: Cancer Intervention and Surveillance Modeling Network.

Panel A depicts women, Panel B depicts men. The red dotted line shows results from the CISNET model. The other three lines show STOP-generated results after each step of our parameterization and calibration process. The blue line includes parameterization of smoking initiation and cessation, but not relapse. The pink dashed line includes smoking relapse as based on published studies. The black line includes calibration of smoking cessation probabilities to reflect quit attempts and relapse before sustained abstinence.

1
2
3 **Figure 3. External validation: STOP model results and NHIS/NDI results for cumulative mortality of**
4 **current smokers and never smokers from age 20.**
5

6
7 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.

8
9
10 NDI: National Death Index. CV-RMSE: coefficient of variation of root-mean-square error.
11

12
13
14 Panel A depicts women, Panel B depicts men. Within each panel, the STOP results and the NHIS data are
15
16 not easily distinguishable because they are essentially overlapping. Current smokers are those who
17
18 continue to smoke until death. NHIS was linked to NDI for mortality data.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1





Figure 2


A

Current smoker prevalence, women born in 1950



B

Current smoker prevalence, men born in 1950




- 1. No relapse
- - - 2. Relapse incorporated, uncalibrated cessation
- 3. Relapse incorporated, calibrated cessation
- CISNET 1950


- 1. No relapse
- - - 2. Relapse incorporated, uncalibrated cessation
- 3. Relapse incorporated, calibrated cessation
- CISNET 1950

Figure 3

A Cumulative mortality by smoking status, women



B Cumulative mortality by smoking status, men



**A novel microsimulation model of tobacco use behaviors and outcomes:
calibration and validation in a US population**

Supplement

Krishna P. Reddy, Alexander J.B. Bulteel, Douglas E. Levy, Pamela Torola, Emily P. Hyle, Taige Hou,
Benjamin Osher, Liyang Yu, Fatma M. Shebl, A. David Paltiel, Kenneth A. Freedberg, Milton C. Weinstein,
Nancy A. Rigotti, Rochelle P. Walensky

Table of Contents

Methods: Supplementary Text	p. 2
References	p. 6
Supplementary Table 1	p. 7
Supplementary Table 2	p. 9
Supplementary Figure 1	p. 10
Supplementary Figure 2	p. 11
Supplementary Figure 3	p. 12

METHODS: SUPPLEMENTARY TEXT

National Health Interview Survey (NHIS)

NHIS is a yearly in-person questionnaire administered to the civilian noninstitutionalized population of the US which, since 1965, has collected information on individual smoking status. Since 1991, the smoking section of the NHIS has first queried “ever smoker” status – defined as having smoked at least 100 cigarettes in one’s lifetime – then asked ever smokers, “Do you NOW smoke cigarettes every day, some days or not at all?” which resulted in the classification of occasional smokers as current smokers, even though they initially may have said they did not smoke now. Regardless of response to the second question, participants were asked about the frequency of their smoking.[1]

Use of NHIS data in the Simulation of Tobacco and Nicotine Outcomes and Policy (STOP) model

We downloaded NHIS and linked National Death Index (NDI) data from the Integrated Public Use Microdata Series (IPUMS) Health Surveys for the years 1997-2009.[2] We obtained basic demographic information, smoking status and behavioral variables, and death status/year of death reported through 2011. For all derivations below, we excluded those with unknown smoking or mortality status. Only people 18 years of age or older were surveyed about tobacco use, and since ages 85+ years are censored, we excluded those as well.

External validation - mortality

From the pooled 1997-2009 data, we used the IPUMS-recoded and -constructed survey weights adjusting for differential representation in the smoking sub-sample and NDI follow-up. Because of the NHIS sampling design, weights must be used so that the survey respondents can be collectively expanded to represent the civilian noninstitutionalized population of the US. These weights represent a

1
2
3 surveyed individual's inverse probability of being included in both the survey supplement, which
4
5 contains questions about smoking, and the NHIS-NDI linked mortality files.
6
7
8
9

10 Smoking cessation inputs: We derived age- and sex-stratified cessation rates using the NHIS
11 variable that reported years since respondents (former smokers) quit smoking. We excluded
12 quit ages before age 16 years (due to perceived inconsistency of coding of the "time since quit"
13 variable – some entries implied negative quit age) and included quit ages through age 85 years.
14
15
16
17
18
19
20

21 Smoking initiation inputs: Similarly, we derived initiation rates, also age- and sex-stratified, using
22 the variable that reported years since the respondent (a current or former smoker) started to
23 smoke regularly. We used initiation rates from ages 6 to 61 years, the last age for which data are
24 consecutively available for both women and men.
25
26
27
28
29
30
31

32 Mortality inputs: We calculated mortality rates by age, sex, smoking status, and five-year age
33 group using the smoking status variable and NDI reporting through 2011. The rates were
34 calculated from a follow-up period beginning in the respondent's survey year and ending in
35 2011 or the year of her/his death, whichever came first. Because smoking behavior data were
36 collected only at baseline in NHIS and not again at the time of death, there may have been some
37 misclassification of smoking status (e.g., someone who was a current smoker at the time of NHIS
38 assessment may have subsequently quit and later died but was still considered a current
39 smoker). However, all-cause mortality rates do not significantly decrease until a few years after
40 cessation, and we considered those who had quit smoking to have similar mortality risks to
41 current smokers until five years of abstinence. This reflects contemporary studies in which
42 former smokers were defined as those who had not smoked in the previous five years and data
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 from large US cohort studies that indicate that the all-cause mortality risk in men who quit
4
5 smoking does not fall below that of current smokers until five years of abstinence.[3,4]
6
7
8
9

10 Input cohort: We derived initial cohort characteristics for this analysis from the NHIS 1997-2009
11
12 pooled dataset: current, former and never smoking prevalence by five-year age group from age
13
14 <20 to 84 years; mean (standard deviation [SD]) age adjusted for bounding of the distribution;
15
16 sex distribution; and mean (SD) time since quit bounded by a minimum quit age of 16 years.
17
18
19
20

21 Output comparison: We compared STOP model output for mortality to NHIS/NDI-reported
22
23 mortality in the form of mortality rates and cumulative mortality from age 20 years.
24
25
26
27

28 *External validation – smoking prevalence*

29
30 From the NHIS 1997 data, using the same survey weights as above:
31
32
33

34 Smoking cessation, smoking initiation, and mortality inputs: We used the same cessation,
35
36 initiation, and mortality rate inputs as for the mortality validation.
37
38
39
40

41 Input cohort: We derived input cohort characteristics for this analysis from the 1997 NHIS data:
42
43 current, former, and never smoking prevalence by five-year age group from age <20 to 84 years;
44
45 mean (SD) age adjusted for bounding of the distribution; sex distribution; and mean (SD) time
46
47 since quit bounded by a minimum quit age of 16 years.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Output comparison: Starting with the 1997 NHIS respondents and following them each year
4
5 from 1998 to 2009, we compared STOP projections to NHIS data regarding prevalence of
6
7 current, former, and never smokers by five-year age group from age 30 to 84 years.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES IN SUPPLEMENT

- 1 Centers for Disease Control and Prevention. National Health Interview Survey. Adult tobacco use - major changes. https://www.cdc.gov/nchs/nhis/tobacco/tobacco_changes.htm (accessed 9 Jan 2020).
- 2 Blewett LA, Rivera Drew JA, Griffin R, et al. *IPUMS Health Surveys: National Health Interview Survey, Version 6.3 [dataset]*. Minneapolis, MN: IPUMS. <https://nhis.ipums.org> (accessed 9 Jan 2020).
- 3 Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med* 2013;**368**:351–64. doi:10.1056/NEJMsa1211127
- 4 Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;**368**:341–50. doi:10.1056/NEJMsa1211128
- 5 Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA* 2006;**296**:64–71. doi:10.1001/jama.296.1.64
- 6 Brendryen H, Kraft P. Happy Ending: a randomized controlled trial of a digital multi-media smoking cessation intervention. *Addiction* 2008;**103**:478–84. doi:10.1111/j.1360-0443.2007.02119.x
- 7 Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet* 2013;**382**:1629–37. doi:10.1016/S0140-6736(13)61842-5
- 8 Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;**99**:29–38. doi:10.1111/j.1360-0443.2004.00540.x

Supplementary Table 1. Examples of transition probabilities in the simulation model.

Parameter	Value	Reference
Smoking initiation probability, monthly, by age and sex	0-0.0063	Derived from NHIS 1997-2009 data
Cessation probability, monthly, by age and sex	0-0.035	Derived from NHIS 1997-2009 data
Relapse probability, monthly, by time since cessation	$P_{\text{Relapse}} = 0.62 * e^{-0.33 * t}$	[5-8]
Never Smoker mortality probability, monthly, by age and sex, x 10 ⁻⁴	0.4-95.2	Derived from NHIS/NDI 1997-2009 data
Current Smoker or Recent Quitter mortality probability, monthly, by age and sex, x 10 ⁻⁴	0.4-136.1	Derived from NHIS/NDI 1997-2009 data
Former Smoker mortality probability, monthly, by age, sex, and time since cessation ^a , x 10 ⁻⁴	0-111.5	Derived from NHIS/NDI 1997-2009 data
Time to transition from Recent Quitter to Former Smoker	5 years ^b	Assumption, [3,4]

NHIS: National Health Interview Survey. NDI: National Death Index. STOP: Simulation of Tobacco and Nicotine Outcomes and Policy.

^aThese former smoker mortality probabilities were used only in the external validation exercises, comparing STOP model output to NHIS/NDI results. In cross-validation comparing STOP model output to

1
2
3 the CISNET model results, we applied multipliers to never smoker mortality rates to derive former
4
5 smoker mortality rates and then converted these to probabilities.
6
7

8
9
10 ^bThis five-year abstinence period was based on data showing mortality risks by years since smoking
11
12 cessation.[3,4] We performed an analysis in which we assumed that mortality risks decreased to
13
14 “Former Smoker” levels immediately upon quitting smoking, but the model-generated results were not
15
16 a better fit to NHIS data (results not shown).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Table 2. Selected age- and sex-specific annual mortality rates: STOP model output versus NHIS-derived mortality.


Women						
	Current Smoker		Former Smoker		Never Smoker	
Age group, years	STOP	NHIS/NDI	STOP	NHIS/NDI	STOP	NHIS/NDI
40-44	0.0023	0.0023	0.0017	0.0015	0.0012	0.0012
50-54	0.0071	0.0071	0.0035	0.0029	0.0025	0.0025
60-64	0.0147	0.0146	0.0087	0.0079	0.0051	0.0051
Men						
	Current Smoker		Former Smoker		Never Smoker	
Age group, years	STOP	NHIS/NDI	STOP	NHIS/NDI	STOP	NHIS/NDI
40-44	0.0031	0.0034	0.0028	0.0025	0.0018	0.0018
50-54	0.0094	0.0096	0.0059	0.0053	0.0042	0.0043
60-64	0.0233	0.0232	0.0114	0.0099	0.0067	0.0066

STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.


NDI: National Death Index.

1 **Supplementary Figure 1. Smoking status by age group and sex in 1997: STOP model inputs for the external validation exercise of smoking**
 2 **prevalence.**

3 **A**




4 **B**



5
 6 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey.

7 Panel A depicts women; Panel B depicts men. For each age group, the prevalence of current, former, and never smokers is entered as STOP
 8 model input. The external validation analysis of smoking prevalence, using weighted NHIS 1997 survey respondent data as inputs, projects
 9 smoking prevalence annually from 1998 to 2009.


10 **Supplementary Figure 2. External validation: STOP model results and NHIS results for prevalence of current, former, and never smokers each**
11 **year from 1998 to 2009.**



12
13 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey. NDI: National Death Index.

14
15 Panel A depicts women, Panel B depicts men. The STOP model cohort had the age and smoking status distribution of the 1997 NHIS survey
16 respondents (Supplementary Figure 1). The STOP-generated results reflect a microsimulation that included probabilities of smoking initiation,
17 smoking cessation, smoking relapse, and mortality.

18 **Supplementary Figure 3. Two-way sensitivity analysis of smoking initiation and smoking cessation multipliers for external validation exercise.**



19

20 STOP: Simulation of Tobacco and Nicotine Outcomes and Policy. NHIS: National Health Interview Survey. CV-RMSE: coefficient of variation of

21 root-mean-square error.

22

1
2
3 23 Panel A depicts women; Panel B depicts men. The multipliers were applied to the original cessation and initiation rates derived from pooled
4
5 24 1997-2009 NHIS data and used in the STOP model. The horizontal axis shows the multiplier applied to smoking initiation rates (subsequently
6
7
8 25 converted to probabilities) in the STOP model, and the vertical axis shows the multiplier applied to smoking cessation rates (subsequently
9
10 26 converted to probabilities). Colored cells represent the CV-RMSE of STOP model-generated versus NHIS-reported current smoking prevalence
11
12 27 among people ages 30-84 years from 1998 to 2009.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only